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Summary 
 
The acquired immunodeficiency syndrome (AIDS) is currently the most infectious disease 
worldwide. It is caused by the human immunodeficiency virus (HIV). At the moment there 
are ~33.3 million people infected with HIV. Sub-Saharan Africa, with ~22.5 million people 
infected accounts for 68% of the global burden. In most African countries antiretroviral 
therapy (ART) is administered in limited-resource settings with standardised first- and 
second-line ART regimens. During this study I analysed the therapy-naïve population of 
Cape Town, South Africa and Mwanza, Tanzania for any resistance associated mutations 
(RAMs) against protease inhibitors, nucleoside reverse transcriptase inhibitors and non-
nucleoside reverse transcriptase inhibitors. My results indicate that HIV-1 subtype C accounts 
for ~95% of all circulating strains in Cape Town, South Africa. I could show that ~3.6% of 
the patient derived viruses had RAMs, despite patients being therapy-naïve. In Mwanza, 
Tanzania the HIV drug resistance (HIVDR) prevalence in the therapy-naïve population was 
14.8% and significantly higher in the older population, >25 years. Therefore, the current 
WHO transmitted HIVDR (tHIVDR) survey that is solely focused on the transmission of 
HIVDR and that excludes patients over 25 years of age may result in substantial 
underestimation of the prevalence of HIVDR in the therapy-naïve population. Based on the 
prevalence rates of tHIVDR in the study populations it is recommended that all HIV-1 
positive individuals undergo a genotyping resistance test before starting ART. I also 
characterized vif sequences from HIV-1 infected patients from Cape Town, South Africa as 
the Vif protein has been shown to counteract the antiretroviral activity of the cellular 
APOBEC3G/F cytidine deaminases. There is no selective pressure on the HIV-1 Vif protein 
from current ART regimens and vif sequences was used as an evolutionary control. As the 
majority of phenotypic resistance assays are still based on HIV-1 subtype B, I wanted to 
design an infectious HIV-1 subtype C proviral molecular  clone that can be used for in vitro 
assays based on circulating strains in South Africa. Therefore, I characterized an early 
primary HIV-1 subtype C isolate from Cape Town, South Africa and created a new infectious 
subtype C proviral molecular clone (pZAC). The new pZAC virus has a significantly higher 
transient viral titer after transfection and replication rate than the previously published HIV-1 
subtype C virus from Botswana. The optimized proviral molecular clone, pZAC could be 
used in future cell culture and phenotypic HIV resistance assays regarding HIV-1 subtype C. 
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Zusammenfassung 
 
Das erworbene Immundefektsyndrom (“acquired immunodeficiency syndrome”, AIDS), 
verursacht durch das Humane Immundefizienzvirus (HIV), ist derzeit die häufigste 
Infektionskrankheit weltweit. Zirka 33,3 Millionen Menschen sind gegenwärtig mit HIV 
infiziert, wobei hiervon etwa 22,5 Millionen Infizierte (68%) in den Ländern südlich der 
Sahara leben. In den meisten dieser Länder ist die antiretrovirale Therapie (ART) in nur zwei 
standardisierten Medikamentenkombinationen verfügbar. In dieser Arbeit wurden nicht-
therapierte Patienten aus Kapstadt (Südafrika) und Mwanza (Tansania) auf 
resistenzassoziierte Mutationen (RAMs) gegen Protease Inhibitoren, nukleosidische- und 
nichtnukleosidische Reverse Transkriptase Inhibitoren analysiert. Meine Ergebnisse zeigten, 
dass in 3,6 %  der Patienten RAMs gefunden wurden, obwohl diese nicht vortherapiert 
waren. In der Patientengruppe aus Tansania wurden sogar in 14,8 % der Patientenviren 
RAMs gefunden. Dieses Patientenkollektiv war signifikant älter als 25 Jahre und damit 
außerhalb der von der WHO beobachteten Altersgruppe. Meine Studie legt nahe, dass die 
WHO-Kriterien zur Überwachung der Übertragung von resistenten HIVs die Weitergabe von 
resistenten Viren unterschätzt, da Patienten über 25 Jahre ausgeschlossen werden. Weiterhin 
wurden vif Sequenzen von HIV-1 infizierten Patienten aus Kapstadt charakterisiert, da bereits 
gezeigt wurde, dass das HIV Vif Protein die antiretrovirale Aktivität der Cytidin Deaminase 
APOBEC3G/F antagonisieren kann. Da jedoch keine Medikamenten induzierte Selektion auf 
diesen Sequenzen liegt, wurden diese zur Analyse der viralen Evolution verwendet. 
Phenotypische Resistenzanalysen basieren gegenwärtig meist auf dem HIV Subtyp B, jedoch 
sind die meisten Infizierten in Südafrika und sogar weltweit mit Subtyp C infiziert. Deshalb 
war es ein Ziel dieser Arbeit einen proviralen HIV Subtyp C Plasmid zu entwickeln. Dazu 
wurde das Virus aus einem frühen HIV Subtyp C Isolat kloniert. Das hier neu klonierte Virus 
(HIV-ZAC) zeigt sowohl einen höheren viralen Titer nach der Transfektion und auch eine 
höhere Replikationsrate als das zuvor publizierte HIV-1 Suptyp C Virus aus Botswana. 
Deshalb könnte der von mir optimierte und neu charakterisierte provirale molekulare Klon, 
pZAC, zukünftig in der Zellkultur und bei phenotypischen HIV Resistenztests als 
wildtypisches HIV-1 Suptyp C Virus eingesetzt werden. 
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Chapter one 
 
1. Introduction and literature review 
 
1.1  Introduction 
Today acquired immunodeficiency syndrome (AIDS) is one of the most important infectious 
disease being the most common cause of death in Africa, above malaria and tuberculosis. 
AIDS is caused by the retrovirus Human Immunodeficiency Virus (HIV). The UNAIDS 
estimates that there are currently 33.3 million people infected with HIV/AIDS worldwide. 
Sub-Saharan Africa remains the heaviest affected region with approximately 22.5 million 
people infected, which accounts for 68% of the global burden. However, globally since 1999 
the number of new infections has fallen by approximately 19%, with antiretroviral therapy 
(ART) currently being provided to more than 5.0 million people (UNAIDS, 2011).  
 
The genetic subtype distribution of HIV-1 group Major (M), currently responsible for the 
majority of the AIDS pandemic has become dynamic and unpredictable. Currently HIV-1 
group M has been divided into 9 subtypes (A-D, F, G-H, J, K), 49 circulating recombinant 
forms (CRFs) and numerous unique recombinant forms (URFs). In 2004-2007, subtype C 
accounted for nearly half (48%) of all global infections, followed by subtypes A (12%), B 
(11%) and CRF02_AG (8%) (Hemelaar et al., 2011).  
 
1.2  History of HIV infection 
AIDS was first recognized in 1981 amongst homosexual men in the United States of America 
(USA) who presented with Pneumocytis carinii pneumonia, a rare disease causing lung 
infections in humans with weakened immune systems (Gottlieb et al., 1981a, b). A few of 
these men developed Kaposi’s sarcoma, a previously rarely seen skin cancer caused by 
Human Herpesvirus 8 (HHV-8) (Friedman-Kien et al., 1981; Hymes et al., 1981). It was 
initially thought that the disease was a form of punishment for people participating in high 
risk behaviour (Shilts, 1987). However, the symptoms and disease was soon recognized in 
other population groups as well. These included female sexual partners of men (Masur et al., 
1982), Haitians (Pape et al., 1983), infants (Oleske et al., 1983), haemophiliacs (Bloom, 
1984) and blood transfusion recipients (Curran et al., 1984). In Africa the first reported 
outbreak occurred in the heterosexual population of the Democratic Republic of Congo 
(DRC), previously Zaire (Piot et al., 1984). AIDS was initially described as the appearance of 
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certain rare, dramatic and life-threatening opportunistic infections and associated cancers,  
which led to a severe depletion of the immune system response (Ammamm et al., 1983). The 
first evidence that AIDS was caused by a retrovirus was discovered in 1983. Barré-Sinoussi 
and colleagues isolated a retrovirus from a homosexual man who had lymphadenopathy 
syndrome (LAS), a disease of the lymph nodes. The virus was initially called 
lymphadenopathy virus (LAV) (Barré-Sinoussi et al., 1983). It was also independently 
isolated in 1984 by Levy and co-workers who called it AIDS-associated retrovirus (ARV) 
(Levy et al., 1984). Later on it was confirmed that LAV and ARV were the same virus and 
responsible for causing AIDS (Ratner et al., 1985a, b). To avoid further confusion the 
International Committee on the Taxonomy of viruses decided to rename the AIDS inducing 
virus HIV, as it is known today (Coffin et al., 1986a, b). 
 
1.3  Origin of HIV 
HIV forms part of the Retroviridae virus family, genera Lentivirus (Sonigo et al., 1985). The 
earliest documented report of a human infection comes from a seropositive patient in 
Kinshasa, DRC from 1959 (Zhu et al., 1998). Molecular clock and phylogenetic analyses 
estimate that HIV was introduced into the human population during the 1930s with a ± 20 
year confidence gap (Hahn et al., 2000; Korber et al., 2000). HIV is closely related to simian 
immunodeficiency viruses (SIVs) found in non-human primates and through zoonosis the 
virus adapted to its human host. SIVs do not usually cause the same dramatic AIDS-defining 
disease in our non-human primate counterparts (Hahn et al., 2000; Silvestri et al., 2003). 
There are more recent reports that indicate that wild chimpanzees can acquire AIDS like 
diseases from SIVs (Keele et al., 2009). Both HIV-1 and HIV-2 are thought to have 
originated in West-Central Africa (Apetrei et al., 2004; Nahmias et al., 1986). HIV-1 was 
transmitted from the common chimpanzee, Pan troglodytes troglodytes (Gao et al., 1999; 
Keele et al., 2006), while HIV-2 was most likely transmitted from the sooty mangabey, 
Cerocebus atys (Gao et al., 1992; Hirsch et al., 1989., Keele et al., 2006). Transmission 
events of SIV strains into the human host still frequently occur and it remains unclear why 
HIV in its current form has become so predominant (Kalish et al., 2005, Weiss and 
Wrangham, 1999). 
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1.4  HIV diversity 
Figure 1.1: HIV-1 Phylogenetic tree derived from nucleotide alignment of genome 
sequences. The different HIV-1 groups are indicated, rooted with SIVcpzANT. The group M 
subtypes (A-D, F-H and J) are shown, while reference sequences for groups N, O and P are 
also marked (Vallari et al., 2011). 
 
 
Figure1.2: Current spread of HIV-1 diversity. HIV-1 subtype C accounts for 48% of all 
currently circulating strains. It is predominantly found in Sub-Saharan Africa and India. HIV-
1 subtype B is more predominant in North America and in Europe (Hemelaar et al., 2011).  
 
HIV has a high genetic diversity. This is caused by the fast replication cycle of the virus 
coupled with the high error prone rate of its RT enzyme. RT also further increases HIV 
diversity by allowing for strains to recombine with each other. There are currently 2 types of 
HIV that have been identified: HIV-1 and HIV-2. HIV-1 has been divided into four distinct 
groups M, non-M, non-O (N), outlier (O) and P with group M responsible for the worldwide 
pandemic we are facing today. HIV-1 groups N, O and P are rare and the degree of their 
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diversity has not yet been completely differentiated through phylogenetic analysis. However, 
group N seems to be phylogenetically equidistant from groups M and O (Spira et al., 2003). 
Group M is currently divided into nine different subtypes (A-D, F-H, J and K) and 49 CRFs. 
Genetic variation within a subtype is usually 8 to 17%, whereas the variations between 
different subtypes are 17 to 35% (Korber et al., 2001). The highest variation within the 
genome is seen within the env gene, wherease the pol gene, encoding for important viral 
enzymes are the most conserved (Gaschen et al., 2002). 
 
HIV-1 group M subtype C (from here on HIV-1 subtype C) is responsible for the majority 
(currently 48%) of all HIV-1 infections worldwide. HIV-1 subtype B is the most widespread 
and is especially prevalent in North America, Europe and Australasia. The majority of HIV-1 
subtypes can be found in West and Central Africa, where it is believed HIV originated 
through zoonosis. HIV-2 is less pathogenic than HIV-1 and has mainly been restricted to 
West Africa. HIV-2 has also been divided into eight subtypes (A-H) based on phylogenetic 
analysis (Damond et al., 2004). 
 
1.5  The HIV genome, virus structure and viral life cycle 
 
HIV-1 proviral DNA 
 
 
 
 
HIV-1 RNA species 
 
 
Figure 1.3A: The HIV-1 proviral DNA genome and 1.3B: HIV-1 RNA species. The virus is 
flanked by the Long terminal repeat (LTR) regions. The group antigen (gag) and envelope (env) 
genes are responsible for the virus structure, while polymerase (pol) encodes for important viral 
enzymes . HIV-1 transcriptional transactivator (tat) and regulator of viral expression (rev) are 
important for viral transcription and regulation. The accessory genes virion infectivity factor (vif), 
viral protein R (vpr), viral protein U (vpu) and negative regulatory factor (nef) play important parts 
during infectivity and maturation (Nielsen et al., 2005). 
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Figure 1.4A: A schematic illustration of the HIV virion and 1.4B: A 3D reconstruction 
of HIV-1 virions. The viral Envelope (Env) consists of the surface glycoproteins (gp120) 
anchored with the transmembrane proteins (gp41). The inner Gag Matrix (MA; p17) and 
Capsid (CA; p24) protein layers are also indicated. The HIV genome consists of two copies 
of unspliced positive single-stranded molecules indicated in the center. The Pol proteins, 
Protease (PR) and Reverse Transcriptase (RT) indicated in the diagram are also packaged in 
the mature virus particle. Source: http://www.asparis.net and 
 http://www.embl.de/research/units/scb/briggs/briggs_1l.jpg. 
 
There are many reviews on the HIV genome, virus structure and viral life cycle. Examples in 
the literature are: Briggs et al., 2003; D'Souza and Summers, 2005; Freed, 2001; Klimas et 
al., 2008; Nisole and Saïb, 2004; Pomerantz and Horn, 2003 and Turner and Summers, 1999. 
The HIV genome (Figure 1.3), virus structure (Figure 1.4) and life cycle (Figure 1.5) are 
briefly described here. 
 
1.5.1  HIV structure and genome organization 
HIV is an enveloped virus and roughly spherically shaped with a diameter of approximately 
120 nm. Its genome consist of two unspliced positive-oriented single-stranded ribonucleic 
acid (RNA) molecules and encodes for nine genes (gag, pol, env, vif, vpr, vpu, tat, rev and 
nef) as described below.  
 
1.5.1.1  The HIV LTR 
The full-length provirus is approximately 9.2 kb long and is flanked by two LTRs. Although 
the LTRs do not directly encode for any gene products, except for the partial Nef coding 
region, they do encode for important structural RNA elements and contain binding sites for 
important transcription factors. Thus the LTRs are important for the regulation of viral gene 
expression (Briggs et al., 2003). Each LTR consist of a unique 3` region (U3), the terminal 
Env 
MA 
CA 
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redundancy region (R) and unique 5` region (U5). The U3 promoter enhancer site contains a 
modulatory negative regulatory element (NRE), an HIV TATA box as well as sequence 
binding sites for cellular transcription factors such as Nuclear factor (NF)-κβ, Specific 
Protein 1 (Sp1) and Transcription Factor IID (TFIID) (D’Soza and Summers, 2005; 
Kashanchi et al., 1996). R is the exact region where viral transcription is initiated by the 
human tRNA and contains the transactivation response (TAR) element sequence. Viral 
transcript starts at the beginning of R, is capped and proceeds through the viral genome. The 
R/U5 border in the 3’LTR defines the region where polyadenylation takes place and the 
polyadenylation signal (AAUAAA) is found within this region. The viral packaging signal, 
primer binding site (PBS) responsible for RNA initiation and major splice donor (SD) signal 
involved in the regulation of transcription are also found downstream of U5. Although the 
LTRs are identical in sequence the 5’LTR acts as the initiation point for transcription and 
capping of messenger RNA (mRNA) transcripts, whereas sequences in the 3’LTR are 
responsible for transcription termination and polyadenylation. The LTRs are also responsible 
for mediating retroviral integration into its host cell genome. The full-length HIV mRNA 
transcript encodes for nine genes. Their protein products are derived from the primary 
transcript by means of alternative splicing, ribosomal frameshifting and leaky scanning of 
initiation codons (Klimas et al., 2008; Turner and Summers, 1999). 
 
1.5.1.2 The virus structure and structural genes 
HIV’s structural genes are encoded by gag (group antigen) and env (envelope), as is common 
in all lentiviral genomes. Recently the secondary structure of HIV-1 RNA genome has also 
been solved by selective 2'-hydroxyl acylation analyzed by primer extension (SHAPE) 
analysis (Watts et al., 2009). The RNA is bound to the nucleocapsid NC (p7) protein and 
surrounded by enzymes important for viral maturation such as protease (PR), reverse 
transcriptase (RT) and integrase (IN), encoded by the viral pol gene as discussed below. 
Accessory proteins (Nef, Vif, Vpr) can also be found in the viral ribonucleoprotein core 
structure. An abundant number of host molecules have also been found in the virus particle, 
although their importance is still unclear (Maxwell and Frappier, 2007). The RNA molecules 
are enclosed by a conical shaped capsid layer consisting of roughly 2000 gag p24 capsid 
(CA) molecules. The inner viral surface consists of a p17 matrix (MA) protein shell 
surrounding the p24 CA and is responsible for the viral integrity. The MA, CA, NC and p6 
proteins are cleaved from the precursor Gag (Pr55) protein, encoded by the gag gene, as well 
as the p1 and p2 spacer peptide proteins and cleaved by the viral protease (PR) (Briggs et al., 
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2003; de Oliveira et al., 2003). The p6 protein binds to HIV-1 Vpr, thereby promoting the 
incorporation of Vpr proteins into mature virus particles (Paxton et al., 1993).  
 
The virus obtains its enveloped phospholipid membrane when budding from the host cell. 
The lipid bilayer contains several cellular membrane proteins, including major 
histocompatibility (MHC) antigens derived from the host cell (Arthur et al., 1992). The virus 
Env proteins are embedded within the lipid membrane layer. They consist of the trimeric 
exposed surface glycoproteins, encoded by env gp120. The surface proteins are anchored by 
the trimeric transmembrane protein, encoded by env gp41. These proteins are derived from 
the env gp160 precursor molecule. Env gp120, which binds to CD4+ cells, is further divided 
into five constant (C1 to C5) and five variable regions (V1 to V5). The variable regions are 
mostly found within regions encoding disulphide-constrained loops, exposed to the surface 
and to the host immune system (Leonard et al., 1990). The V3 region plays an important role 
in determining cellular tropism, allowing the virus to either use chemokine receptor type 5 
(CCR5) or chemokine receptor type 4 (CXCR4) as its main chemokine co-receptor (Briggs et 
al., 2003). 
 
HIV pol encodes for the viral enzymes protease (PR), reverse transcriptase (RT), RNase H 
and integrase (IN). The enzymes are formed by cleaving of the precursor Gag-Pol (Pr160) 
protein by the viral PR (de Oliveira et al., 2003). The Pr160 polyprotein is formed by 
ribosomal frameshifting, the process whereby ribosomes change the open reading frame to 
allow for alternative translation of mRNA (Hung et al., 1998). The HIV-1 PR is part of the 
aspartyl protease group and responsible for cleavage of the precursor Gag (Pr55) and Gag-Pol 
(Pr160) molecules and thus viral maturation. Each subunit of the PR homodimer protein 
contains 99 amino acids with the active site found in the middle of the dimers. The RT 
enzyme acts as a RNA-DNA-dependant DNA polymerase and is found in all retroviruses. It 
is responsible for reverse transcribing the viral single stranded RNA genome into a double 
stranded DNA molecule and helps fold the DNA molecule into its double helix form. The RT 
protein is a heterodimer and consist of p51 and p66 subunits. (Rodgers et al., 1995; Huang et 
al., 1998). The active and DNA-binding site of RT is found within p66, while the p55 subunit 
merely functions as a support molecule for p66. RNase H helps degrade the HIV RNA once a 
DNA copy has been transcribed and the RNA is no longer needed. IN (p32) catalyzes the 
insertion of the newly sythesized HIV DNA molecule into its host genomic DNA. The Pol 
proein has been an important focus of ART (see below). 
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1.5.1.3  The accessory genes 
Tat is between 86 and 101 amino acids in length, plays a crucial role in both in vivo and in 
vitro activation of viral transcription and is absolutely essential for viral replication. Tat 
promotes HIV-1 elongation via the recognition of the TAR hairpin structure at the 5’-end of 
the viral transcripts (Zhou et al., 1998; Brigati et al., 2003). Tat interacts directly with 
positive transcription elongation factor b (P-TEFb), which is responsible for the regulation of 
eukaryotic mRNA elongation (Marshall and Price, 1995; Zhou et al., 1998). Rev, a 19 kilo-
Dalton (kDa) phosphoprotein is responsible for exporting the HIV mRNA products from the 
nucleus to the cytoplasma, before the mRNA transcripts are spliced by cellular proteins 
(Strebel, 2003). Rev binds to mRNA transcripts containing a Rev responsive element (RRE). 
The RRE, encoded as part of the Env gene has a nuclear export signal, allowing for the 
unspliced export of RNA from the nucleus (Le et al., 2002). Without Rev, RNA is spliced 
into smaller transcripts by the cellular machinery. Rev uses interactions with the host 
chromosomal region maintenance 1 (Crm1) protein and the small nuclear RNA (snRNA) 
pathway to export viral transcripts (Strebel, 2003). 
 
The accessory genes include nef, vif, vpr and vpu.  They are not absolutely essential for viral 
replication in vitro, but play a variety of roles during the life cycle of HIV.  
 
The 192 amino acid (23 kDa) HIV-1 Vif protein helps to counteract antiretroviral activity and 
is especially active against the apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like (APOBEC) 3F/G cellular cytidine deaminase family (Arriaga et al., 2006; 
Soros and Greene, 2006). The APOBEC family of proteins act as editing enzymes and causes 
Cytosine to Uracil editing and leads to the accumulation of Guanine to Adenine mutations in 
the proviral sense cDNA strand (Malim, 2006). Vif interacts in the producer cell with 
APOBEC3F/G and recruits it to an ubiquitin ligase complex via a cullin-dependent ubiquitin 
ligase, Cullin 5 (Cul5). APOBEC3F/G is then ubiquitinated and subsequently degraded by 
cellular proteasomes. Vif binds to viral genomic RNA and forms part of the nucleoprotein 
complex (Khan et al., 2001) and also forms part of the reverse transcriptase complex which 
helps control reverse transcription (Carr et al., 2008). 
 
The 96 amino (14 kDa) Vpr protein enhances viral expression and interacts with a host of 
cellular proteins (Bour and Strebel, 2003). Vpr binds to the Gag p6 domain and is directly 
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incorporated into mature HIV-1 virions (Bachand et al., 1999). The protein is responsible for 
the nuclear transport of the HIV-1 pre-integration complex (PIC) and plays an important role 
in the extracellular release of virus particles (Romani and Engelbrecht, 2009). Other functions 
identified include the induction of cellular apoptosis, induction of the G2 cell cycle arrest, 
modulation of gene expression and the suppression of immune activation (Romani and 
Engelbrecht, 2009).  
 
Although the Vpu protein (16 kDa) is not found in the mature virus particle, it promotes the 
extracellular release of virus particles and downregulates CD4 in the Endoplasmic Reticulum 
(ER) (Schubert et al., 1996). These functions are carried out by the two separate domains 
expressed by the Vpu protein. The N-terminal hydrophobic transmembrane domain functions 
as a membrane anchor and promotes virus release, while the hydrophilic C-terminal domain 
contains two amphipathic α-helical domains of opposite polarity and contains sequence 
motifs critical for CD4 degradation (Schubert et al., 1996). Vpu interacts and antagonizes the 
cellular restriction factor Tetherin [also known as CD317 or bone marrow stromal cell 
antigen 2 (BST-2)]. The cellular function of Tetherin is still unknown. Viruses lacking Vpu 
are partially impaired from budding from their host cell and tend to tether at the cellular 
membrane (Neil et al., 2008). Viruses can also however still spread through direct cell-cell 
interactions (Jolly et al., 2010). 
 
The 27 kDA Nef protein is responsible for the establishment of high viral loads during 
infection, which leads to faster disease progression (Kirchhoff et al., 2008). Nef is a 
multifunctional myristoylated protein which interacts with components of host cell signal 
transduction pathway as well as the endocytic clathrin-dependent protein pathway. Early in 
the HIV life cycle Nef is repsonsible for T cell activation and helps establish a persistant viral 
infection. Nef plays an important role in downregulating CD4, CD28, CXCR4, MHC class I 
and MHC class II on antigen presenting cells and other target cells, thus enabling the virus to 
evade the host immune system and help establish latent infection (Bour and Strebel, 2003; 
Roeth and Collins, 2006). Nef thus helps control responses of HIV-1 infected T cells thereby 
preventing superinfection, protects against cytotoxic T-lymphocyte (CTL) responses and also 
facilitates in the release of fully infectious virions (Arhel and Kirchhoff, 2009; Kirchhoff et 
al., 2008; Roeth and Collins, 2006). 
 
  
  
 
18 
1.5.2  The HIV life cycle 
HIV infects cells of the immune system such, as CD4+ T-cells, cytotoxic T-lymphocytes 
(CTLs), CD4+ monocytes and macrophages. The virus can be found in blood plasma, 
peripheral blood mononuclear cells (PBMCs), lymph nodes, the central nervous system and 
various other body fluids and cells after infection (Stebbing et al., 2004). The virus enters the 
host cell via the CD4 receptor molecule and either the CXCR4 or CCR5 chemokine co-
receptor; although in certain cases other host cell co-receptors such as CCR3 can also be 
involved in viral entry (Dash et al., 2008; Regoes and Bonhoeffer, 2005; Rucker et al., 1997). 
Binding of Env gp120 to the CD4 molecule leads to a conformational change at the point of 
attachment, allowing fusion of the membranes and the virological synapses (VS) to form. 
After successful attachment the viral RNA, along with viral enzymes are released into the 
host cytoplasm. In the cytoplasm RT reverse transcribes the RNA into the double stranded 
DNA copy. With the help of IN the newly synthesized viral DNA is imported into the 
nucleus and incorporated into the host cell genome. Once incorporated the DNA may become 
dormant, allowing HIV to form latent infection. 
 
Expression of viral proteins is regulated by both viral and cellular proteins and is initiated 
when Tat binds to the TAR element in the 5’LTR as described above. Both unspliced and 
spliced mRNA transcripts are exported out of the nucleus with the help of Rev. In the 
cytoplasm the cellular machinery translates the mRNA transcripts into viral proteins. Viral 
assembly takes place at the plasma membrane of the host cell. Env gp160 is processed by the 
ER complex, is transported to the Golgi apparatus and cleaved by cellular furine like 
proteases  into its gp120 and gp41 components. Env gp41 acts as an anchor for gp120 at the 
plasma membrane. The Pr55 Gag and Pr160 Gag-Pol polyproteins and viral RNA are 
incorporated into the immature virus particle at the plasma membrane. Gag molecules 
associated with the membrane attracts two copies of viral RNA and together with cellular and 
viral proteins trigger budding from the cell surface (Ganser-Pornillos et al., 2008). 
Maturation occurs when the virus buds from the host cell and viral proteins are cleaved by PR 
into functional proteins and enzymes. The newly formed viruses are free to infect new cells. 
Infection spreads either through cell-cell interaction via a VS, or through cell-free mediated 
interactions. The infected host cell is exhausted through continuous immune activation and 
death of CD4+ T cells paralyses the host immune system (Badley, 2005; Roshal et al., 2001). 
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Figure 1.5: The HIV-1 life cycle. HIV replication consists of viral attachment, entry, reverse 
transcription and integration of the viral DNA into the host DNA / or genome. This is 
followed by export of the viral proteins as well as viral assembly, budding and maturation of 
viral particles. The target sites of the three classes of inhibitors, reverse transcription, 
integration and maturation, are indicated (Pomerantz and Horn, 2003; Turner and Summers, 
1999). 
 
1.6  Antiretroviral therapy and resistance 
Despite the best efforts, there is still no known cure for HIV/AIDS infection. The HIV-1 life 
cycle has been a key target in developing efficient antiretroviral drugs against HIV-1 (Figure 
1.4) and with the aid of antiretroviral therapy (ART) the life expectancy of infected 
individuals has dramatically increased. 
 
1.6.1  Natural resistance to HIV 
Certain rare individuals do not develop AIDS, despite being infected with HIV. They are 
termed slow or long-term nonprogressors (LTNPs) and they seem to have natural immunity 
against the virus. They are able to keep the HIV viral load titer to a minimum (O’connell et 
al., 2009). People carrying the CCR5-Δ32 genetic variant sometimes falls within this 
category. The CCR5-Δ32 allele is found in approximately 10% of the Northern Europe 
population and has been known to show protection not only against HIV, but also smallpox 
(Sabeti et al., 2005). However the mutation also has a negative effect on T-cell function, 
while individuals with this mutation also have a higher brisk contracting West Nile virus 
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(Glass et al., 2006). Individuals with certain HLA (Human leukocyte antigen)-type genes, 
particularly HLA-B*5705 and / or HLA-B*2705 seem also to control HIV infection to a 
certain extent (Migueles et al., 2000). In an Australian cohort individuals were identified 
carrying Nef-deleted variants, leading to the conclusion that defective HIV can also impair 
viral replication in vivo (Rhodes et al., 2000). 
Natural host restriction factors such as APOBEC3F/G active against Vif and Tetherin, active 
against Vpu (discussed above) can also limit HIV-1 viral replication. Other host restriction 
factor against retrovirus include members of the Tripartite Motif (TRIM) protein family such 
as TRIM5α and TRIM22. The TRIM family forms part of the host innate immune system. 
Although TRIM5α is ineffective against HIV-1, it can inhibit murine leukaemia virus (Yap et 
al., 2004). TRIM5α does however successfully block HIV-1 infection in rhesus macaques 
and Old World monkeys (Stremlau et al., 2004). TRIM22 down-regulates HIV-1 
transcription from the LTR and prevents viral assembly by blocking HIV-1 Gag export from 
the nucleus (Barr et al., 2008).  
 
1.6.2  Antiretroviral therapy (ART) 
ART has dramatically led to the reduction of opportunistic infections, an increased life span 
and an improved quality of life in many HIV-1 infected individuals. Current therapeutic 
agents against HIV-1 include viral entry inhibitors, non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), Integrase inhibitors 
as well as protease inhibitors (PIs) (Johnson et al., 2003). More than 30 drugs have been 
approved for use in HIV-1 treatment, with many more drugs currently undergoing clinical 
trials. A list of the Food and Drug Administration (FDA) (USA bureau) approved drugs for 
use in HIV-1 treatment is available at 
http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivitie
s/ucm118915.htm, last accessed 23 August 2011. Most of the current ART drugs attempt to 
stop viral replication by inhibiting the RT gene, stop virus maturation by inhibiting the PR 
gene or attempt to stop the virus from entry into the host cell. ART Mutations often lead to 
the failure of ART in patients infected with HIV-1 (Johnson et al., 2003; Thompson et al., 
2010). Multi-drug resistant viruses usually arise as a result of selective pressure from these 
therapeutic agents. 
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Viral entry inhibitors, also known as fusion inhibitors attempt to stop the virus from entering 
the host cell. However, Env has evolved to evade the host immune response, and therefore is 
highly variable, making it very difficult to produce specific entry inhibitors. The currently 
approved entry inhibitors include Enfuvirtide (Fuzeon), which is active against env gp41 and 
Maraviroc (Celsentri) which acts as a CCR5 antagonist (Pugach et al., 2008). Other small 
molecules and natural ligands targeting the entry receptors CCR5 and CXCR4, such as 
stromal cell-derived factor-1 (SDF-1) could also be used in future vaccine development 
strategies (Seibert and Sakmar, 2004). NNRTIs are a set of drugs, which binds and physically 
interacts with the RT enzyme of HIV-1. Currently available NNRTIs are Delavirdine (DLV), 
Efavirenz (EFV), Etravirine and Nevirapine (NVP). NVP has been widely used to prevent 
mother-to-child-transmission (MTCT) during pregnancy and birth (Guay et al., 1999; 
Lallemant et al., 2004; Johnson et al., 2005). Rilpivirine (Goebel et al., 2006) was the latest 
NNRTI drug approved for HIV-1 therapy by the FDA in May 2011. NRTIs are analogues of 
the body’s own nucleoside or nucleotide molecules and act as alternative substrates for DNA 
polymerases that bind to the RT. Zidovudine (AZT), an NRTI analogue of thymidine and the 
first FDA approved drug against HIV/AIDS, was introduced in 1987 (Fischl et al., 1987). 
Didanosine (ddI), an analogue of adenosine was the second approved FDA drug. Other 
NRTIs include tenofovir (TDF), stavudine (d4T), lamivudine (3TC), abacavir (ABC) and 
emtricitabine (FTC). FTC and 3TC are structurally similar compounds. TDF is an adenosine 
analogue, d4T a thymidine analogue, ABC a guanosine analogue while 3TC and FTC are 
cytidine analogues. Integrase inhibitors actively block retroviral integration into the host 
genome. Raltegravir (RAL) (Steigbigel et al., 2008) is currently the only FDA approved 
Integrase inhibitor available. Elvitegravir (EVG), a second Integrase inhibitor is still in the 
Phase III clinical trial phase and has not been approved by the FDA (Shimura et al., 2008). 
Other second generation Integrase inhibitors still being tested in various phases of clinical 
trials include Dolutegravir (Garrido et al., 2011, Hightower et al., 2011) and MK-2048 (Bar-
Magen et al., 2010). The list of currently available PIs are amprenavir (APV), atazanavir 
(ATV), darunavir (DRV), indinavir (IDV), lopinavir (LPV), nelfinavir (NFV), ritonavir 
(RTV), saquinavir (SQV) and tipranavir (TPV). LPV is only prescribed in combination with 
RTV as Kaletra (Walmsley et al., 2002). PIs disable the enzymatic function of the protein by 
binding to the active site and acting as an alternative substrate. The potency of certain PIs 
allow for their use in monotherapy with certain patients (Cameron et al., 2008).  
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The world health organization (WHO) recommendeds that ART is started when a person has 
a CD4 cell count below 350 cells per mm3 or has progressed to the WHO stage II or III 
disease stage already. People with co-infections are started on therapy immediately. It is 
recommended that people receiving ART be given two NRTIs (either AZT or TDF) and 
either a PI or NNRTI at the start of their treatment (WHO, 2010). When the first line therapy 
fails, second line therapy usually consists of ritonavir-boosted PI and two NRTIs (either AZT 
or TDF depending on the first line therapy regime). Viruses form patients failing ART are 
recommended  to be analysed genotypic testing before changing the therapy regiment. 
Guidelines should be adjusted for each individual, although this is only possible in developed 
countries. To reduce the risk of MTCT pregnant women are given AZT from 28 weeks of 
pregnancy, a single-dose of NVP during labour and given AZT and 3TC for one week 
thereafter. The new born baby is also given a single dose of NVP immediately after delivery 
and AZT for at least a week thereafter. Women who breastfeed should receive a triple ART 
regiment from 14 weeks of gestation after all exposure to breast milk has ended (Thomas et 
al., 2011). The complete updated treatment guidelines can be found at 
(http://www.who.int/hiv/pub/arv/adult2010/en/index.html). 
  
1.6.3  Testing for HIV-1 resistance 
Current assays that test HIV-1 drug resistance include genotypic and phenotypic assays. With 
genotypic resistance testing the viral genome is sequenced and scanned for resistance 
associated mutations. The patient derived viral genome is compared to a database of HIV 
sequences known to be associated with certain resistance patterns (http://hivdb.stanford.edu).  
Phenotypic resistance testing, such as the Phenosense GT system (Monogram Biosciences) 
can be performed by measuring the viral activity in the presence and absence of a drug in 
question. The assay compares the concentration, usually 50% inhibitory (IC50), of drug 
needed to inhibit the clinical isolates with that of the wild type reference strain. Although 
phenotypic tests are more time and labour consuming, the assay directly measures viral 
enzyme function and more accurately reflects the sensitivity of the virus to antiretroviral 
compounds. Discordance between genotypic and phenotypic tests have been also been 
identified (Zolopa, 2006). Previously uncharacterised mutations, especially unknown 
resistance mutations which form against novel HIV-1 drugs, cannot be predicted by 
genotypic methods alone. 
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1.7  Aim of thesis 
The primary aim of this thesis was to characterize circulating HIV-1 strains from Cape Town, 
South Africa. This was done through genotypic methods. Through phylogenetic analyses we 
analyzed HIV-1 resistance mutations in the treatment naïve patient population. We also 
characterized HIV-1 Vif sequences from patients derived viruses. Our third aim was to 
construct an infectious HIV-1 subtype C proviral molecular clone from Cape Town, South 
Africa having a high replication capacity, which should be used for in vitro HIV assays, 
including phenotypic HIV-1 resistance testing in the future. We also investigated the HIV 
resistance profile of a treatment naïve cohort in Mwanza, Tanzania. 
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Chapter Two 
2.  Materials 
 
2.1 Patient samples 
 
2.1.1  Therapy naïve patients used for HIV-1 genotyping 
For HIV-1 genotypic tests Ethylene diamine tetra-acetic acid (EDTA) blood from 140 therapy 
naïve patients were received from an academic hospital clinic, private clinics, state clinics, 
the Western Province Blood Transfusion Service (WPBTS) and a sex worker cohort from the 
Cape Metropole area of South Africa, during the period of 2002 to 2004. These include 81 
black females, 34 black males, 5 Caucasian males, 1 Caucasian female as well as 8 males and 
11 females of mixed race. These patient samples were also used to characterize HIV-1 vif 
sequences from Cape Town, South Africa. The cohort samples represent different ethnic 
groups and consist of heterosexuals, homosexuals, bisexuals, and MTCT-infected 
individuals. 
 
2.1.2  Patient ZAC (R3714) 
The retrovirus cohort represents patient samples diagnosed with either HIV or HTLV 
infection of which samples (plasma and serum) were stored from 1984 to 1995 at the 
Tygerberg hospital in Cape Town, South Africa. The patient, a South African coloured 
(mixed race) male born on 22 August 1931 was diagnosed with lymphocyte depleted 
Hodgkin’s lymphoma on 02 March 1989 and diagnosed as HIV-1 positive on 09 March 1989. 
He travelled frequently to Lusaka, Zambia, where he possibly became infected with the virus. 
Subsequently, serum and PBMCs were obtained during November 1989 (harvested on 20 and 
21 November 1989) and the virus was co-cultured with PBMCs and isolated. High molecular 
weight DNA was extracted from the HIV-positive cultures through phenol-chloroform 
extraction and stored. HIV-1 positive cultures were confirmed by RT assay that ranged from 
12495 to 35073 counts per minute per millilitre (cpm/ml). The env gene was amplified by 
PCR, sequenced and identified as subtype C (Engelbrecht et al., 1995). 
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2.1.3  Therapy naïve patients from Mwanza, Tanzania 
Treatment naïve samples were obtained from the ProCort1 (trial name: ‘‘ProCort1’’; registry: 
ClinicalTrials.gov; registration number: NCT01299948) clinical trial at the Bugando Medical 
Centre in Mwanza, Tanzania. The study was approved by the National Institute for Medical 
Research (Tanzania), Bugando Centre Ethical Board and Ministry of Health (Tanzania). 
Plasma and PBMCs were collected for each patient at baseline and at 12 later time points 
over a two year period. 
 
2.2  Equipment, commercial assays, enzymes and chemicals 
The list of equipment, chemicals and assays used during this study are listed in this chapter. 
In Table 2.1 the PCR kits and enzymes used are listed. In Table 2.2 the equipment needed to 
perform the necessary assays and analysis are presented, while the commercial packages used 
are given in Table 2.3. Buffers and additional media are listed in Table 2.4. Chemicals 
needed for buffers were obtained from Merck, Roth and Sigma-Aldrich. Miscellaneous 
products used are listed in Table 2.5. 
 
Table 2.1: PCR kits and enzymes. 
Enzymes Supplier 
Access RT-PCR system Promega 
Antarctic phosphatase NEB 
ExpandTM High Fidelity PCR system Roche Diagnostics 
ExpandTM Long Template PCR system Roche Diagnostics 
GoTaqTM DNA polymerase Promega 
Herculase® II Agliotti 
Moloney Murine Leukemia Virus (M-MLV) RT Promega 
Phusion® High Fidelity DNA polymerase NEB 
Restriction enzymes Fermentas, NEB, Promega 
Shrimp alkaline phosphatase (SAP) Fermentas 
T4 DNA ligase Fermentas, NEB 
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Table 2.2: Equipment used to perform sample assays and analysis. 
Equipment Supplier 
ABI prism® 310 genetic analyzer Applied Biosystems 
Biometra® T-personal thermal cycler Biometra 
Gelair flow cabinet BSB4A Flow Laboratories 
Heating block Peqlab Biotechnologies 
Heraeus® CO2-Auot-Zero incubator Heraues 
Heraeus® Multifuge 1 S-R centrifuge  Heraues 
Intas Gel DocTM system Bio-Rad 
NanoDropTM system NanoDrop Technologies 
Sartorius PB-11 pH meter Sartorius 
Sonicator-Sonifier® 250  Branson 
Sorvall® 90SE ultracentrifuge Thermo fisher scientific 
Sorvall® Evolution RC centrifuge Thermo fisher scientific 
Table top Eppendorf® 5417C centrifuge Eppendorf 
Trans-Blot® SD cell Bio-Rad 
Vortex A. Hartenstein 
Leitz Labovert FS light microscope Leica 
Leitz DM IRE2 fluorescent microscope Leica 
 
Table 2.3: Commercial kits and assays. 
Product Supplier 
BigDyeTM Terminator Cycle Sequencing 
Ready Reaction Kit version 1.1 Applied Biosystems 
Fugene®6 or HD transfection reagent kit Roche Diagnostics 
Cobas®Amplicor HIV-1 Monitor version 1.5 test kit Roche Diagnostics 
GeneEluteTM gel extraction and PCR purification kits Sigma-Aldrich 
GeneRulerTM 1 kb DNA ladder Fermentas 
NucleoBond® PC500 Reagents Macherey-Nagel 
PageRulerTM Prestained Protein Ladder Fermentas 
pcDNA™3.1 Directional TOPO® Expression kit Invitrogen 
Pierce® ECL Western Blot Detection kit Thermo scientific 
PureYieldTM Plasmid Midiprep system Promega 
QIAamp®  DNA Micro kit Qiagen 
QIAprep® Spin Miniprep kit  Qiagen 
RNeasy® Mini extraction kit Qiagen 
TOPO® XL PCR Cloning kit and TA Cloning® kit Invitrogen 
TurboFectTM in vitro transfection reagent kit Fermentas 
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Table 2.4: Buffers, media and recipes. 
Description Recipe 
Alseivers Trypsin Versene (ATV) 
8.0g NaCl, 0.27g KCl, 1.15g NaH2PO4, 0.2g KH2PO4, 0.1g MgSO4 x 7H2O, 1.125g 
Na2-EDTA, 1.25g Trypsin. Add 1 L distilled H2O. 
Competent cell buffer 1 
30 mM Potassium acetate (pH 5.8), 100 mM RbCl, 10 mM CaCl2, 50 mM MnCl2, 
15% Glycerine (v/v). 
Competent cell buffer 2 
10 mM MOPS [3-(N-morpholino) propanesulfonic acid buffer] (pH 7.0), 10 mM 
RbCl,75 mM CaCl2, 15 % Glycerine (v/v). 
Dulbecos Modified Eagle Medium 
(DMEM)* 
10% Fetal calf serum (FCS) (heat-inactivated), 5% L-Glutamine (500 µg/ml), 
0.05% Penicillin (100 µg/ml), 0.05% Streptomycin (100 µg/ml). Add 500 ml H2O. 
DNA loading dye (6 x) 0.125% Bromophenol blue, 40% Sucrose. 
Hepes buffered saline (HBS) (2 x) 280 mM NaCl, 50 mM HEPES, 1.5 mM Na2HPO4, pH 7.1. 
Luria-Bertani (LB) medium (5 x) 100g broth base, 25g NaCl, 5g α-D-Glucose. Add 1 L H2O. 
LB-Agar 20g LB broth base, 20g Agar, 5g NaCl. Add 1 L H2O. 
MEM (Minimal essential media)* 
10% FCS (heat-inactivated), 5% L-Glutamine (50 µg/ml), 0.05% Penicillin (100 
µg/ml), 0.05% Streptomycin (100 µg/ml). 
Miniprep solution 1, resuspension 
buffer 
50 mM Glucose, 10 mM EDTA (pH 8.0), 25 mM Tris HCl (pH 8.0). 
Miniprep solution 2, lysis buffer 0.2 M NaOH, 1%  Sodium dodecyl sulfate (SDS). 
Miniprep solution 3, neutralization 
buffer 
3M Natriumacetate (pH 5.4). 
MOPS (10 x) 83.7g MOPS, 13.6g Sodium acetate, 3.7g EDTA. 
Phosphate buffer saline (PBS) 
137 mM NaCl, 2.07 mM KCl, 4.3 mM Na2HPO4 x 2H2O, 1.4 mM KH2PO4, 1.5 
mM CaCl2 x 4H2O; 1 mM MgCl2 x 6H2O. 
Radio-Immunoprecipitation Assay 
(RIPA) – buffer 
20 mM Tris-HCl (pH 7.4), 300 mM NaCl, 1% sodium deoxycholate, 
1% Triton-X 100, 0.1% SDS. 
Roswell Park Memorial Institute 
(RPMI) – 1640 media* 
10% FCS (heat-inactivated), 10 mM HEPES (pH 10.4), 5% GlutaMax (500 µg/ml), 
0.05 % Penicillin (100 µg/ml), 0.05 % Streptomycin (100 µg/ml). 
SAP reaction buffer 25 mM Tris-HCl (pH 7.6), 1 mM MgCl2, 0.1 mM ZnCl2, 50% Glycerine. 
SDS loading buffer (6 x) 
3 ml Glycerine, 1g SDS, 0.375mg bromophenol blue, 3.75 ml ß-Mercaptoethanol. 
Add 10 ml Tris-HCl with 0.4 % SDS. 
SDS running buffer (5 x) 25 mM Tris, 200 mM Glycine, 0.1 %  SDS (w/v). 
SDS separation gel (4 x) 1.5M Tris HCl (pH 8.8), 0.4% SDS (w/v). 
SDS stacking gel (4 x) 0.5M Tris HCl (pH 6.8), 0.4% SDS (w/v). 
T4 DNA ligase buffer 50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10 mM Dithiothreitol, pH 7.5. 
Tris-Acetate-EDTA (TAE) buffer 
(50 x) 
2 M Tris, 50 mM EDTA (pH 8.0), 5.71% acetic acid (v/v). 
Tris-EDTA (TE) buffer 10 mM Tris-HCl (pH 8.0), 1 mM EDTA. 
Western Blot buffer 3.04 g Tris, 14.4g Glycine, 100 ml Methanol, Add 1 l ddH2O. 
*DMEM was obtained from Sigma-Aldrich, MEM from Invitrogen and RPMI-1640 from Gibco. 
Salts and antibiotics added to the various cell culture mediums are shown in the recipe list. 
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Table 2.5  Miscellaneous products used. 
Material Supplier 
FCS Gibco 
Glassware Schott 
Nitrocellulose membrane Roth 
Laboratory liquids (Acetone, Ethanol, Isopropanol, 
Methanol, Polyacylamid Terralin) 
Roth 
Laboratory wear A. Hartenstein 
Neubauer counting chamber A. Hartenstein 
Parafilm Roth 
Pipette tips A. Hartenstein 
Pipettes Gilson 
Plastic material 
Costar, Eppendorf, Falcon, 
Greiner, Nunc, Roth 
Sterile filters and filterpaper Schleicher & Schuell 
Fuji medical x-ray film Fujifilm 
 
2.3  Primers 
The primers used for HIV-1 PR and RT genotyping were previously described (Plantier et al., 
2005). The HIV-1 subtype C full-length sequencing primers were also described before 
(Rousseau et al., 2006). The vif genotyping primers are given in Table 2.6. The HIV-1 
subtype C primers are given in Table 2.7. The melting temperature (Tm) for each primer is 
given. 
 
Table 2.6: HIV-1 vif genotyping primers. 
Primer Amplification step Sequence 5’-3’) Tm (oC) 
HIV-int1 1st round PCR WWWYKRGTYWRTWMYRGRRWCAGSAGAG 51.1 – 65.8 
HIV-INT6A 1st round PCR ATNCCTATNCTGCTATGTYGRCAYCCAAT 55.9 – 62.9 
INT3S 2nd Round PCR AGMMAARSYHCTCTGGAACGGTGAAG 56.4 – 64.3 
INT5A 2nd Round PCR CCTATNCTGCTATGTYGACAACCAATKCTGWAAATG 61.0 – 64.4 
 
Table 2.7: HIV-1 subtype C amplification primers. 
Primers Sequence (5'-3') Tm (oC) 
HIV_NgoMIV_F GAATGCCGGCTGGATGGGCTAGTTTACTCCAAGAGAAGGCAAG 71 
CMVstart_NgoMIV GAATGCCGGCTAGTTATTAATAGTAATCAATTACGGGTC 63 
CMF_overlap_F 
CAGAGCTGGTTTAGTAACCGGGTCTCTCTAGGTAGACCAGATCTGAGCC
CGGGAGCTC 77 
CMV_overlap_R 
GTGCTCCCGGGCTCAGATCTGGTCTACCTAGAGAGACCCGGTTACTAAA
CCAGCTCTG 77 
SpeI-R CTATTTGTTCCTGAAGGGTACTAGTGTTCCTGCTATG 64 
SpeI-F CATAGCAGGAACTACTAGTACCCTTCAGGAACAAATAG 64 
PacI-R CTCTAATTCTTTTAATTAACCAGTCTATTTTTC 54 
PacI-F GAAAAATAGACTGGTTAATTAAAAGAATTAGAG 54 
BspEI-R GTCTTTGTAATACTCCGGATGTAGCTCGCG 63 
BspEI-F CGCGAGCTACATCCGGAGTATTACAAAGAC 63 
NotI-R GAGCGGCCGCACTACCAAAAAGGGTCTGAGGGATCTCTAGTTAC 72 
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2.4  Plasmids and vectors 
The HIV-1 plasmids pNL4-3 (Adachi et al., 1986) and pMJ4 (Ndung'u et al., 2001) were 
used during the study. The enhanced Green Fluorescent Protein (eGFP) expression plasmid, 
pEGFP-C1 was obtained from Clontech. The cloning vectors pUC19, TOPO® XL PCR, 
pcDNA3.1TM 3.1D/V5-His/lacZ and PCR® II were obtained from Invitrogen.  
 
2.5  Bacterial cells 
Bacterial cells were otained from Invitrogen.  
E.coli Top10 competent cells: chromosomal genotype: F- mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 ΔlacΧ74 recA1 araD139Δ(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG. 
E.coli DH5α competent cells: chromosomal genotype: F- φ80lacZΔM15 Δ(lacZYA-argF) 
U169 recA1 endA1 hsdR17(rk -, mk +) phoA supE44 thi-1 gyrA96 relA1 tonA.  
 
2.6  Antibiotics 
Ampicillin, Kanamycin, Penicillin, and Streptomycin were obtained from Sigma-Aldrich. 
 
2.7  Culture cell lines 
The maintenance of the various cell lines are described in chapter 3. 
HEK-293T: Human embryonic kidney (HEK) stem cells expressing a large Simian 
Vacuolating Virus 40 TAg (SV40 T) antigen on their cell surface (Graham et al., 1977; Pear 
et al., 1993). 
TZM-bl: A HeLa derived cell line expressing CD4, CCR5 and CXCR4. It contains HIV Tat-
inducible Luciferase and ß-galactosidase (X-gal) genes (Derdeyn et al., 2000; Wei et al., 2002). 
MT-4: A Human T-cell Lymphotropic Virus-I (HTLV-I) transformed T-cell line (Harada et 
al., 1985; Larder et al., 1989). 
PBMCs were isolated from donor blood samples. 
 
2.8  Antibodies 
Primary western blot detection antibodies against HIV-1 Gag p24 (Hartl et al., 2011), GFP 
(Sigma-Aldrich) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH, Sigma-Aldrich) 
were used. Secondary antibodies were Goat Anti-Rabbit Immunoglobulin G (IgG) and Goat 
Anti-Mouse IgG and obtained from Jackson Immuno Research. 
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Chapter three 
 
3.  Methods 
 
3.1  Patient sample preparation 
The South African samples were collected at Tygerberg Academic hospital, Cape Town, 
South Africa. Plasma was collected from EDTA blood after centrifugation (Beckman Coulter 
Allegra™ 6R, Beckman Inc.) at 2000 rpm for 10 minutes at 4°C and subsequently stored at -
80°C for future analysis. Viral RNA was extracted using the high throughput M1000 robot 
extractor (Abbott Diagnostics). 
 
Samples from the Tanzania cohort were collected at the Bugando Medical Centre in Mwanza, 
Tanzania. Patient PBMCs were isolated from 8 ml of whole blood were collected in cell 
preparation tubes (Becton Dickenson) with a fixed ficoll gradient. After isolation of PBMCs, 
the cells were immediately frozen at -80°C in RPMI 1640 medium supplemented with 40% 
fetal calf serum (FCS) and 10% Dimethyl sulphoxide (DMSO). The EDTA plasma samples 
were obtained from 6 ml whole blood collected in EDTA Vacutainer (BD) and immediately 
frozen at -80°C. Plasma was collected as for the South African samples. The PBMC and the 
plasma samples were shipped frozen at -70°C with temperature log to Würzburg, Germany. 
DNA was extracted from 1 x 106 PBMC using the QIAamp® DNA Micro Extraction Kit 
(Qiagen). RNA extraction of plasma was performed using the sample preparation kit of the 
Cobas® Amplicor HIV-1 Monitor version 1.5 test kit (Roche). 
 
3.2  Polymerase chain reaction (PCR) 
PCR, developed in 1985 by Kary B. Mullis (Mullis and Faloona, 1987) was used to amplify 
HIV-1 RNA or DNA from selective patient sample and DNA plasmids.  A PCR amplification 
involves concurrent steps of DNA heat denaturation, primer annealing and DNA extension.  
These steps are repeated several times during PCR cycling (Saiki et al., 1988).  The following 
standard protocol was used to amplify all DNA: One cycle of denaturation at 94°C for 2 
minutes, followed by 30 to 35 cycles of denaturing at 94°C for 30 seconds, primer annealing 
for 30 seconds (according to primer pair Tm) and elongation at 72°C for 30 seconds to 1 
minute per kb of target amplified DNA. A final elongation step of 72°C for 3 to 10 minutes 
was performed, after which the samples were cooled and stored at 4°C or -20°C for longer 
periods, until used. The reaction consists of 0.5 µM of each specific target primers (listed in 
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Chapter 2), 200 µM deoxyribonucleoside triphosphates (dNTPs) (Sigma-Aldrich), DNA 
polymerase with specified reaction buffer, usually obtained from the manufacturer and 10 ng 
of patient or plasmid DNA in a total reaction mixture of 50 µl in a 0.2 ml thin-wall PCR tube 
(VWR).  
 
For short fragments, generally less than 1 kb in length, GoTaqTM DNA polymerase 
(Promega) was used. For larger fragments using a high fidelity enzyme was necessary to limit 
PCR error mistakes (Hopfner et al., 1999). For this the ExpandTM High Fidelity PCR system 
(Roche Diagnostics), Herculase® II PCR system (Agliotti) or the Phusion® High Fidelity 
DNA polymerase system (NEB) was used. For larger fragments, bigger than 3 kb the 
Phusion® High Fidelity DNA polymerase system was preferred. 
 
When amplifying RNA, the RNA fragment was first reverse transcribed into complementary 
DNA (cDNA) using the Moloney Murine Leukemia Virus (M-MLV) RT protocol (Promega). 
Briefly, 10 ng to 5 µg of total RNA was added with 1 µl of primer (0.5 µg/µl), 2 µl of 10 mM 
dNTP mix and 1 µl of RevertAIDTM Hminus M-MLV RT (200 U/µl) to in a 20 µl reaction 
volume filled with water in a 0.2 ml thin-wall PCR tube (VWR). The following protocol was 
used: Incubation at 37°C for 5 minutes, followed by reverse transcription at 42°C for 60 
minutes. The reaction was stopped by heating at 70°C for 10 minutes. The Access RT-PCR 
system (Promega) was also used as a one-step amplification system to amplify small DNA 
fragments from RNA. The manufacturer’s instructions were followed. All PCR steps were 
performed in a Biometra® T-personal thermal cycler (Biometra). 
 
3.3  Agarose gel electrophoresis 
Agarose gel electrophoresis allows for the separation of nucleic acids according their 
molecular weight size through electrophoresis in an agarose gel with a current of constant 
strength (Sambrook et al., 1989). All PCR products were verified by agarose gel 
electrophoresis on a 0.8% to 1.5% (w/v) agarose (Roth) gel in 1 x TAE buffer. Samples were 
mixed with 6 x DNA loading dye (0.125% Bromophenol blue, 40% Sucrose) and 
approximately 6 µl were loaded per lane on the agarose gel. Electrophoresis reactions were 
run at 80 V for a 50 ml agarose gel, while 100 V was used for a 150 ml gel. The DNA was 
stained with ethidium bromide (A. Hartenstein) (0.5 µg/ml) and viewed under a UV light 
with a wavelength between 280 and 320 nm, with the INTAS Gel DocTM system (Bio-Rad). 
Ethidium bromide is a powerful mutagen and should be handled carefully (Ausubel et al., 
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2003; Sambrook et al., 1989; Sharp et al., 1973). The GeneRulerTM 1 kb DNA ladder 
(Fermentas) was used as a molecular weight size marker. 
 
3.4  Purification of nucleic acids 
To dispose of excess dNTPs, enzymes and buffers amplified PCR products were purified 
either by agarose gel extraction using the GeneEluteTM gelextraction kit or the GeneEluteTM 
PCR purification kit using the manufacturer’s instructions (Sigma-Aldrich). The purification 
protocols are based on silica membrane spin protocols which allows for binding of nucleic 
acids to a silica membrane inside a spin column (Vogelstein and Gillespie, 1979; Sambrook 
et al., 1989). 
 
3.5  DNA concentration determination 
The NanoDropTM system (NanoDrop technologies) was used to determine the DNA 
concentration spectrophotometrically using a 1 µl input sample. DNA measurements are read 
at a wavelength of 260 nm, while purity is determined by dividing the absorbance at 260 nm 
with the absorbance at 280 nm (Sambrook et al., 1989). Pure DNA has a value between 1.7 
and 1.9. Lower values are indicative of protein contamination, while higher values indicate 
the presence of RNA in the sample. 
 
3.6  Transformation of DNA into bacterial plasmid vectors 
Transformation is the process by which bacteria incorporates exogenic material, such as 
DNA from its surroundings. The standard protocol was followed (Sambrook et al., 1989): 
Competent cells, previously stored at -80°C were allowed to thaw for 5 to 10 minutes on ice 
before use. Approximately 0.01 to 0.1 µg of plasmid DNA or 5 to 10 µl of ligated DNA were 
mixed with 100 µl of competent cells and incubated on ice for 30 minutes. The reaction 
mixture was heat shocked at 42°C for 90 seconds and incubated on ice for a further 2 
minutes. A volume of 900 µl of 1 x LB medium was added to the cells and the reaction was 
allowed to shake for 1 hour at 37°C. The bacterial cells were pelleted by centrifugation at 
3000 rpm for 3 minutes. Approximately 50 to 200 µl of the bacteria were grown on antibiotic 
specific agar plates overnight at 37°C. For direct large scale preparation of bacterial clones 
the transformed bacteria were grown in a 250 ml LB-medium containing specific antibiotics, 
while shaking at 200 rpm overnight. 
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3.7  Small scale preparation of plasmid DNA (minipreps) 
Small scale preparation of plasmid DNA or more commonly referred to as minipreps were 
isolated from bacterial cultures using the following ethanol precipitation protocol: 
Single colonies on agar plates were picked and inoculated in 3 ml of 1 x LB-medium 
containing antibiotics. Ampicillin was used at a concentration of 100 µg/ml while kanamycin 
was used at 50 µg/ml. The culture was transferred to a 1.5 ml microcentrifuge tube 
(Eppendorf) and approximately 1.2 ml of bacteria was pelleted by centrifugation at maximum 
speed (12000 - 14000) rpm in a table top centrifuge. The supernatant was discarded and the 
pellet re-suspended by vortexing in 100 µl of miniprep solution 1. Resuspended cells were 
lysed by adding 200 µl of miniprep solution 2 and incubated at room temperature for 5 
minutes, after which 200 µl of miniprep solution 3, neutralization buffer was added. The 
reaction mixtures were centrifuged at maximum speed for 5 minutes. The supernatant was 
added to 100% ice cold ethanol (3 x volume) and centrifuged again at maximum speed for 5 
minutes. The DNA pellet was washed by adding 500 µl of 70% ethanol to the reaction tube 
and centrifuging at maximum speed for 2 minutes. After carefully discarding the ethanol 
supernatant the pellet was air-dried at 55°C for 10 minutes. The DNA was resuspended in 50 
µl Tris-EDTA (TE) buffer with Ribonuclease A (RNaseA). RNaseA removes RNA from 
DNA preparations. 
 
3.8  Large scale preparation of plasmid DNA (Maxipreps) 
Maxipreps cultures from transformed DNA or miniprep cultures were grown in 250 ml 1 x 
LB medium overnight at 37°C and pelleted by centrifugation at 6000 rpm for 10 minutes. 
The preparations were done with either the PureYieldTM Plasmid Midiprep System (Promega) 
or the NucleoBond® PC500 Reagentkit (Macherey-Nagel) according to the manufacturer’s 
instructions.  
 
3.9  Restriction enzyme digestion 
Restriction endonuclease enzymes are enzymes that cut DNA at a specific recognition 
sequence and are commonly used in laboratories to create recombinant plasmids (Sambrook 
et al., 1989). Restriction enzymes were used to test if recombinant DNA plasmids were 
correct. The following protocol was followed: Approximately 0.5 µg of DNA was added to 
specified restriction enzyme buffer with 1 U/µg of enzyme in a 20 µl reaction filled with 
water. The reaction was incubated for 1 to 2 hours at the specified temperature for each 
enzyme used. For larger reaction volumes when DNA fragments were needed for ligation 
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reactions the following protocol was followed: Approximately 5 to 10 µg of DNA were 
added to specified restriction enzyme buffer with 5 to 10 U/µg of enzyme in a 100 µl reaction 
filled with water and the reaction was incubated for 2 hours or longer, until the DNA was 
completely digested. Restriction digestions were analysed by agarose gel electrophoresis as 
described above. 
 
3.10  Ligation of DNA vectors 
In order to ligate DNA cut with restriction enzymes T4 DNA ligase (NEB) was used. T4 
DNA ligase catalyzes the formation of phosphodiester bonds between the 5’-phosphate and 
3’-hydroxyl termini between double stranded DNA molecules (Sambrook et al., 1989). The 
following protocol was followed: Insert DNA was ligated to vector DNA in a ratio of 1:3, 
with specified reaction buffer and 2 U of T4 DNA ligase enzyme in a total reaction volume of 
20 µl filled with water. The reaction was left for approximately 4 hours at room temperature 
or incubated at 4°C overnight. The ligated DNA vectors were transformed into E.coli TOP10 
competent cells as described above. 
 
Before use in ligation reactions vector DNA was sometimes treated with Shrimp Alkaline 
Phosphatase (SAP, Fermentas) or Antarctic Phosphatase (NEB). Phosphatase is able to 
catalyze the removal of 5´ phosphate groups from DNA and RNA and is commonly used to 
stop vectors from self-ligation. This strategy decreases the chance of vector background in 
cloning strategies. (Sambrook et al., 1989; Rina et al., 2000). In a 10 µl reaction volume 1 µg 
of DNA was incubated with 1 U of enzyme and specified reaction buffer at 37°C for 30 
minutes. The reaction was heat-inactivated at 65°C for 5 to 10 minutes. 
 
3.11  Preparation of E.coli competent cells 
For bacterial transformation E.coli Top10 and DH5α competent cells (Invitrogen) were used. 
New competent cells were generated with the following protocol: 
Competent cells (100 µl) were inoculated with 5 ml LB medium, without antibiotics and 
allowed to shake overnight 200 revolutions per minute (rpm) at 37°C. From the overnight 
culture 1 ml were transferred into a 100 ml LB medium culture, allowed to shake for 2 – 3 
hours at 37°C until an Optical Density of 600 (OD600) value of between 0.2 and 0.3 were 
reached. OD600 value calculates the density of the culture and tells you when the logarithmic 
growth phase is reached. When ready, samples were transferred to sterile 50 ml falcon tubes, 
incubated on ice for 10 minutes after which they were centrifuged at 6000 rpm for 10 minutes 
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in a Heraeus® Multifuge 1 S-R centrifuge (Heraeus). The supernatant was removed and 
pelleted cells were resuspended in 20 ml ice-cold competent cell buffer 1 and left on ice for a 
further 10 minutes. Resuspended cells were centrifuged for a further 10 minutes at 6000 rpm 
and pelleted cells were resuspended in 4 ml ice-cold competent cell buffer 2. After 15 
minutes competent cells were aliquoted in a volume of 200 µl into 1.5 ml microcentrifuge 
tubes (Eppendorf), quickly frozen in liquid nitrogen and stored at -80°C until used.  
 
3.12  DNA sequencing 
Through DNA sequencing the exact base pair sequence of a DNA fragment can be obtained. 
The PCR-based sequencing reaction is based on the enzymatic method of Sanger et al. 
(1977). The reaction incorporates both dNTPs as well as dideoxyribo-nucleoside 
triphosphates (ddNTPs), where the addition of ddNTPs to the DNA strand leads to a chain 
termination reaction. As the dNTPs are fluorescently labelled with different dyes they can be 
read on an automated DNA sequencer. In a 5 µl reaction volume 1 µl of BigDyeTM version 
1.1 terminator enzyme mix (Applied Biosystems), 5 pmol of primer, 500 ng of plasmid DNA 
and water were added together in a 0.2 ml thin-wall sequencing tube (A. Hartenstein). The 
following cycle sequencing reaction was performed: Denaturation at 96°C for 10 seconds, 
primer annealing for 5 seconds at 55°C and an elongation step at 60°C for 4 minutes. 
Sequences were performed on an automated ABI prism® 310 Genetic Analyzer system 
(Applied Biosystems). 
 
3.13  Sequence and phylogenetic analyses 
In order to study the relationship between various HIV sequences obtained we used 
phylogenetic analyses. Briefly, molecular phylogenetics is the study of evolutionary 
relationships among organisms based on their DNA and / or protein sequences. Phylogenetic 
analyses has become a useful tool to study HIV origin, epidemiology and diversity because of 
the rapid replication rate and evolution of these viruses (Salemi and Vandamme, 2003). 
Sequence contigs obtained were edited and assembled using the Lasergene Seqman and 
MegAlign version 7.0 software packages (DNASTAR Inc.). DNA sequences were aligned 
using the ClustalW version 2.0 software package (Larkin et al., 2007). Phylogenetic trees 
were generated with the TreeconW for Windows version 1.3b software package (Van de Peer 
and De Wachter, 1994) or the Mega version 5.0 software package (Tamura et al., 2011). The 
PR and RT derived sequences were screened for mutations associated with drug resistance 
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with the HIV database Genotypic Resistance Interpretation Algorithm version 4.6.2 on the 
HIV database maintained by Stanford University, USA  
(http://hivdb.stanford.edu/index.html). Reference sequence for use in sequence analyses were 
obtained from the Los Alamos National Laboratory database (http://www.hiv.lanl.gov). 
Conserved sequences were highlighted with the Bioedit version 7.0.9 (Hall, 1999) and 
Genedoc version 2.6.002 software packages (Nicholas et al., 1997). 
 
3.14  Maintenance of cell lines 
HEK-293T and TZM-bl cells were maintained in minimal essential media (MEM) 
(Invitrogen) at 37°C with a constant (5%) CO2 level in a Heraeus® CO2-Auto-Zero incubator 
(Heraeus). Cells were trypsinised with ATV and diluted (1:10) with fresh media every 2 to 3 
days. Cells were maintained in appropiate culture flask (Nunc). Aliquots of cells were frozen 
away at -80°C with 10% DMSO for future use.  
MT-4 cells were maintained in RPMI-1640 media (Gibco) and replaced with fresh media 
added every 2 to 3 days in a 1:10 dilution. MT-4 cells and maintained in a biosafety level 3 
laboratory. 
 
3.15  Isolation and maintenance of PBMCs for cell culture 
PBMCs were extracted from donor EDTA blood by density gradient centrifugation with 
Histopaque®-1077 (Sigma-Aldrich) to separate them from red blood cells and most 
granulocytes (Janeway et al., 2001). PBMCs were cultivated overnight at 37°C with a 
constant (5%) CO2 level in a Heraeus® CO2-Auot-Zero incubator (Heraeus) with RPMI-1640 
media stimulated with phytohemagglutinin-P, (PHA-P) (Sigma-Aldrich) (0.5 mg/ml) and 
human Interleukin-2 (IL-2) (Sigma-Aldrich) (0.1 mg/ml) before being used for viral kinetics 
assays. IL-2 is a T-cell growth factor cytokine, while PHA-P is a plant mitogen that 
upregulate the expression of IL-2 receptors on T-cells (Johnson and Byington, 1990). In a 6-
well cell culture plate (Nunc) approximately 5 x 105 cells were seeded before using the next 
day. All cell counts were done with the aid of the Neubauer cell counting chamber (A. 
Hartenstein). 
 
3.16  Transfection of cells 
Transfection is the process by which cells incorporate DNA plasmids through the cell 
membrane into their cytoplasm. During this study we used the Calcium-Phosphate 
transfection protocol, Fugene®6 or HD (Roche Diagnostics) or the TurboFectTM in vitro 
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transfection reagent (Fermentas). Calcium phosphate fascilitates the binding of DNA to the 
cell surface. The DNA subsequently enters the cell via endocytosis (Graham and van der Eb, 
1973; Loyter et al., 1982). Briefly: In a 6-well cell culture plate (Nunc) 5 x 105 cells were 
seeded in MEM overnight at 37°C with a constant (5%) CO2 level in a Heraeus® CO2-Auto-
Zero incubator (Heraeus). The next day fresh media was added. For Calcium-Phosphate 
transfection 2.5mM of CacCl2 was added to 2 x HBS solution. Approximately 4 µg of DNA 
was transfected and the culture incubated for 2 to 3 days to allow for the expression of 
proteins. For TurboFectTM 6 µl transfection reagent was added to 4 µg of DNA with Dulbecos 
Modified Eagle Medium (DMEM) (Sigma-Aldrich). With Fugene®6 or HD 3 µl transfection 
reagent was added to 1 µg of DNA with DMEM (Sigma-Aldrich). 
 
3.17  Western Blot analyses 
To detect the expression of proteins specific antibodies were used in western blot detection 
assays as follows: From cell cultures supernatant was removed as described above. Cells 
were lysed with RIPA buffer and sonification (Sonicator-Sonifier® 250, Branson). 
Sonification breaks the cell membranes and releases the proteins into the supernatant 
(Sambrook et al., 1989). SDS loading buffer (6 x) was added to each sample. Samples were 
heated at 95°C for 5 minutes, centrifuged in a table top centrifuge at 8000 rpm for 5 minutes 
and loaded onto a polyacrylamide gel for separation. Polyacrylamide gels separates proteins 
according to seize. The polyacrylamide gel consists of a separation gel, layered on a stacking 
gel for loading of samples. The composition of the gel is given in Table 3.1. The 
Rotiphorese® acrylamid / bis-acrylamid Gel 40 (29:1) solution as the polyacrylamid source 
was obtained from Roth. Ammonium persulfate (APS) was obtained from Merck and 
Tetramethylethylenediamine (TEMED) from Sigma-Aldrich. 
 
Table 3.1: Composition of SDS gel (8.0 cm by 10 cm) 
Reagents Separation gel (12.5%) Stacking gel 
Rotiphorese® 
Gel 40 (29:1) 4.68 ml 0.65 ml 
4 x SDS buffer 3.75 ml 1.25 ml 
dd H20 6.57 ml 3.0 ml 
10% APS 150 µl 100 µl 
TEMED 25 µl 10 µl 
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The proteins are separated according to size by running the gel at a constant voltage (100 V 
for a small scale gel) in SDS-running buffer. The PageRulerTM Prestained Protein Ladder 
(Fermentas) was used as a size marker control. From the polyacrylamide gel proteins were 
transferred to a 0.2 µM Roti® nitrocellulose membrane (Roth) with the Trans-Blot® SD cell 
system (Bio-Rad). To block non-specific proteins from binding to the nitrocellulose 
membrane, the membrane was washed with 5% milk-PBS solution [5g milk powder (Roth) in 
100 ml PBS]. The nitrocellulose membrane was incubated overnight at 4°C in 5% milk-PBS 
solution, while constantly shaking. The following concentrations of antibodies were used. 
GFP (1:6000), anti-p24 (1:4000) and GAPDH (1:4000). The following day the nitrocellulose 
membrane was washed three times with PBS and secondary antibody added (1:10000 in 
PBS). After an hour incubation at room temperature while shaking, a final wash was 
performed (3 x with PBS). Proteins blots were  developed with the Pierce® ECL Western Blot 
Detection Kit (Thermo scientific) in a dark room environment on Fuji medical x-ray film 
(Fujifilm). 
 
3.18  Determination of viral infectivity 
In order to determine the viral titre after transfection supernatant from transfected cells were 
titred onto TZM-bl cells. TZM-bl cells (1 x 104) were seeded the day before use in a 96-well 
cell culture plate (Nunc) and allowed to grow overnight at 37°C with a constant (5%) CO2 
level in a Heraeus® CO2-Auto-Zero incubator (Heraeus). The next day 1 ml of supernatant 
from the transfected HEK 293T cells was centrifuged at 1500 rpm for 5 minutes at room 
temperature in a centrifuge. From the supernatant 100 µl was titrated per well on the TZM-bl 
plate and diluted down (1:10; 1:100 and 1:1000). The rest of the supernatant was stored at -
80°C for future use. Two days later cells were fixed with methanol and acetone (1:1) for 5 
minutes, washed 3 x with PBS and stained with X-gal staining buffer: 
 
X-gal staining buffer 
2.5% X-gal (Sigma-Aldrich) in Dimethylformamide (DMF) (Roth) 
2 mM MgCl2 (Sigma-Aldrich) 
4 mM potassium ferricyanide (K3[Fe(CN)6]) (Sigma-Aldrich) 
4 mM potassium ferrocyanide (K4[Fe(CN)6]) (Sigma-Aldrich) 
Fill to desired volume with PBS. 
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Infectious HIV-1 cells turn blue because of the LacZ promoter is induced by HIV-1 tat. As a 
control GFP containing cells were stained with 4% paraformaldehyde and quantified under 
the fluorescent microscope. The Multiplicity of Infectivity (MOI) was determined for each 
set of transfection reactions to use in growth infectivity assays. To determine virus growth 
kinetics MT-4 cells or PBMCs were infected with an MOI of 0.05 and cells were cultured for 
up to 8 days. Fresh media was added every 4 days.  
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Summary 
Human Immunodeficiency Virus type 1 (HIV-1) subtype C, spread mainly via 
heterosexual transmission is currently the most predominant HIV-1 subtype worldwide. 
Cell culture studies of Sub-Saharan African subtype C proviral clones (pMJ4 and 
pHIV1084i) are hampered by their low replication capacity. We describe here the 
modification of pMJ4, leading to a proviral clone with a higher replication rate in cell 
culture. Furthermore, an early primary HIV-1 subtype C isolate from Cape Town, 
South Africa is characterized and a new infectious subtype C proviral clone (pZAC) is 
created. The new pZAC clone has a higher viral titer than the original pMJ4 clone. 
Characteristics of pZAC Env gp120, such as a shortened compact V1 loop and an 
elongated V4 sequence, favors an enhanced viral replication rate in vitro. The newly 
characterized infectious HIV-1 subtype C clone, pZAC can be useful for future in vitro 
studies. 
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The UNAIDS estimates that there are currently 33.3 million people infected with HIV/AIDS 
worldwide. Since 1999 the number of new infections has fallen by approximately 19%, with 
more than 5.0 million people now receiving antiretroviral therapy. Sub-Saharan Africa 
remains the most severely affected region with approximately 22.5 million people infected, 
which accounts for 68% of the global burden. Although the rate of new infections in Sub-
Saharan Africa has steadily decreased, 1.8 million in 2009 compared to 2.2 million in 2001, 
the total number of people with new diagnosed infections in this region continues to rise 
(UNAIDS, 2011). 
 
The genetic subtype distribution of HIV-1 group M, currently responsible for the majority of 
the AIDS pandemic, has become dynamic. Currently HIV-1 group M has been divided into 9 
subtypes (A-D, F, G-H, J, K), 49 circulating recombinant forms (CRFs) and numerous unique 
recombinant forms (URFs). In 2004-2007, subtype C accounted for nearly half (48%) of all 
global infections, followed by subtypes A (12%), B (11%) and CRF02_AG (8%) (Hemelaar 
et al., 2011). 
 
HIV-1 subtype C is predominant in Eastern and Southern Africa as well as in India. It 
accounts for approximately 95% of all HIV-1 infections in Southern Africa (Jacobs et al., 
2009). It is also increasing in frequency in countries such as China and Brazil (Hemelaar et 
al., 2011). HIV-1 subtype C has unique characteristics, which distinguishes it from other 
subtypes. These include the presence of an extra NF-κß enhancer binding site in the long 
terminal repeat (LTR), a prematurely truncated Rev protein and a 5 amino acid insertion of 
the 5’end of the Vpu open reading frame (McCormick-Davis et al., 2000; Rodenburg et al., 
2001). Curiously, these differences on a molecular level result in a lower replication-fitness 
in primary CD4+ T cells and peripheral blood mononuclear cells (PBMCs), making it more 
difficult to study in vitro (Ariën et al., 2005). Recently Iordanskiy et al., (2010) suggested 
that characteristics of the reverse transcriptase (RT) polymerase domain of HIV-1 subtype C 
strongly affect the replication capacity of these viruses in cell culture, compared to that of 
HIV-1 subtype B. However, these genetic differences do not seem to influence the 
transmission efficiency of subtype C viruses in vivo. In addition, HIV-1 subtype C has a 
relatively high transmission fitness in dendritic cells (Ball et al., 2003).  
 
Almost all in vitro HIV-1 cell culture assays are based on HIV-1 subtype B strains. The 
infectious proviral subtype B strains (for example pNL4-3) have been used in HIV-1 studies 
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for the last 25 years of HIV research (Adachi et al., 1986). Only recently has the focus shifted 
in developing HIV-1 antiretroviral reagents targeting multiple strains of HIV-1 (Hemelaar et 
al., 2011).  
 
There are currently four HIV-1 subtype C proviral infectious clones described, two from Sub-
Saharan Africa (Grisson et al., 2004; Ndung'u et al., 2001) and two from India (Dash et al., 
2008; Mochizuki et al., 1999). During the course of this study we cultured a HIV-1 subtype C 
isolate from Cape Town, South Africa using peripheral blood mononuclear cells (PBMCs). 
We characterized the full-length sequence and used the strain to improve the replication 
capacity of a previously characterized infectious HIV-1 subtype C proviral molecular clone 
pMJ4, originating from Botswana (Ndung'u et al., 2001). 
 
The pMJ4 proviral clone has a low replication rate and grows slowly on PBMCs, although it 
replicates better in CCR5 cell lines (Ndung'u et al., 2001). After transfection of Human 
Embryonic Kidney (HEK) 293 T-cells, with further titration onto the TZM-Bl indicator cell 
line, which is dependent on Tat-activation of the HIV-1 LTR (Wei et al., 2002), pMJ4 has 
significant lower viral titers compared to pNL4-3 (Fig. 1c). To improve the initial gene 
expression the 5’-U3 was replaced with the CMV-IE promoter by PCR, as previously 
described for NL4-3 (Bohne & Kräusslich, 2004), using restriction sites NgoMIV and SpeI. 
The resulting plasmid was abbreviated as pcMJ4. The CMV-IE-promoter has been shown to 
enhance lentiviral expression and is frequently used as a promoter in plasmid expression 
vectors (Bohne & Kräusslich, 2004). Transfection of HEK 293T cells, with further titration 
on TZM-Bl cells showed that pcMJ4 produced a 4-fold higher viral titer than the parental 
MJ4 plasmid (Fig. 1c). In order to compare Gag amounts of pcMJ4 with pMJ4 a p24 Western 
Blot analysis was performed (Hartl et al., 2011) and pcMJ4 clearly showed an increase in 
Gag expression levels (Fig. 1d). Hence, the pcMJ4 clone was used further as a HIV-1 subtype 
C expression control plasmid.  
 
To further establish a fast replicating HIV-1 subtype C proviral clone, the HIV-1 positive 
sample from patient ZAC (previously named R3714, supplementary data; Engelbrecht et al., 
1995) was obtained from one of the earliest documented cases of heterosexual transmission 
of HIV-1 subtype C in South Africa, during 1989. The primary isolate was cultured in 
PBMCs and HIV-1 positive high molecular weight (HMW) DNA stored for further analysis 
(Engelbrecht et al., 1995). We first replaced the env of MJ4 with that of our primary isolate, 
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ZAC using standard cloning techniques and a proofreading Herculase II polymerase 
(Stratagene) (Fig. 1a). The 3.2 kb PCR product was amplified from the HMW DNA of ZAC 
with primers containing the restriction enzyme recognition sites for PacI and BspEI. This 
corresponds to position 6198 and 9393 relative to the reference HXB2 genome. Clones were 
screened by restriction enzyme digestion and sequenced to confirm the presence of the 
correct insert. Forty-eight hybrid clones were transfected and titrated on TZM-Bl cells as 
described above. However, only 5 (10.4 %) of proviral clones produced significant viral 
titers. The 5 clones are identical in sequence and showed approximately a 10 fold increase in 
viral titer after titration on TZM-Bl, compared to that of pcMJ4 (Fig. 1c), confirmed by Gag 
p24 Western Blot analysis (Fig. 1d). The clone was designated pcMJ4/ZACenv. We decided 
to use pcMJ4/ZACenv to create the new infectious subtype C pZAC proviral clone.  
 
The 5’ fragment of ZAC was amplified in two further parts encompassing the gagpol and 
LTR-gag region (Fig. 1a). The gagpol region was replaced using restriction sites SpeI 
(corresponding to position 1507 of HXB2) and PacI (corresponding to position 6198 of 
HXB2), while the CMV-IE LTR-gag sequence from ZAC was added as for pcMJ4. The new 
proviral clone was designated pcZAC. The 3’-U5 was replaced using BspEI and the vector 
located NotI restriction site and the 5’-U3 CMV-IE was replaced with the ZAC derived 5’-U3 
sequence. The final clone (without the CMV-IE promoter) was named pZAC. The full-length 
pcZAC and pZAC clones have slightly lower viral titers on TZM-Bl cells compared to the 
pcMJ4-ZACenv proviral clone (Fig. 1b). The sequence from pZAC has typical African HIV-
1 subtype C characteristics. These include 3 Nf-κB sites in the LTR, a premature Rev stop 
codon and a 5 amino acid insertion in the Vpu transmembrane domain. The Indian subtype C 
strains lack this 5 amino acid insertion.  
 
The full-length ZAC sequence on nucleotide level was found to be 91.9% similar to 
HIV1084i and 91.4% similar to MJ4; 91.6% compared to Indie_C1 and 89.3% compared to 
D24. To analyse the phylogenetic relationships of the full-length infectious HIV-1 subtype C 
clones a neighbour-joining phylogenetic tree was constructed with Mega version 5.0 using 
the Maximum Composite Likelihood method (Fig. 1b) (Tamura et al., 2011). The Indian and 
Africa HIV-1 subtype C strains exhibited two unique phylogenetic clusters (Fig. 1b). The 
new ZAC sequence had a close phylogenetic relationship with the HIV-1 subtype C 
sequences from Sub-Saharan Africa.  
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An alignment of the Env gp120 is given in Fig. 2. The ZAC Env gp120 sequence were 80.8% 
similar to MJ4, 79.2% to HIV1084i, 78.2% to Indie_C1 and 76.2% to D24. The sequences 
had a two amino acid insert on position 24 and 25 in the hydrophobic core of the signal 
peptide sequence, not seen in the MJ4 and HIV1084i African strains, although the Indian 
infectious sequences have a similar insert. Furthermore, ZAC had a shortened, very compact 
V1 loop similar to HIV1084i and a slightly larger V4 loop compared to MJ4 (3 amino acids) 
and HIV1084i (7 amino acids). Furthermore, ZAC also had more potential N-linked 
glycosylation sites (26), compared to that of MJ4 (23) while NL4-3 had 24 and Indie-C1 had 
27 and D24 had 31. 
 
We cultivated our infectious viruses on PBMCs for the indicated time points, initial 
multiplicity of infection (MOI) of 0.05, for up to 8 days (Fig. 3). pMJ4/ZACenv and pZAC 
grew significantly better in PBMCs than the original MJ4 clone. For virus titer we infected 
TZM-Bl cells as described above. pZAC peaks at days 4-6, similarly as described for the 
Indian HIV-1 subtype C clones (Dash et al., 2008; Mochizuki et al., 1999). However, MJ4 
(as well as HIV1084i, Grisson et al., 2004) only peaks in PBMC cell culture at days 8-12. 
With the ZAC env sequence, the pMJ4 strain also peaks at days 4-6, although the viral titer is 
not as high as NL4-3 (Fig. 3). 
 
HIV-1 subtype C remains the predominate subtype worldwide and is especially prevalent in 
Sub-Saharan Africa, where the HIV/AIDS epidemic is at the highest. However, in vitro 
studies with infectious proviral HIV strains have shown that HIV-1 subtype C generally has a 
lower replication rate compared to that of the infectious HIV-1 subtype B (pNL4-3) strain 
(Grisson et al., 2004; Ndung'u et al., 2001). This is also true for other non-subtype B strains 
and it has been difficult to obtain infectious proviral molecular clones from primary HIV-1 
isolates for non-subtype B strains. It has also been reported that HIV-1 subtype C may have 
lower levels of pathogenic fitness when compared to other HIV-1 group M strains (Abraha et 
al., 2009). 
 
The nucleotide sequence diversity between env genes in the same subtype can range from a 
few percent to as high as 15% (Gaschen et al., 2002). HIV-1 subtype C Env gp120 has unique 
characteristics distinguishing it from other HIV-1 strains. It has the most compact V1-V2 
described sequences of all the HIV-1 strains. It also has a relatively conserved Env gp120 V3 
loop containing the well-preserved GPGQ motif on the tip of the V3 crown, with the 
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corresponding virus showing preference to using CCR5 as its major co-receptor irrespective 
of the stage of disease progression (Ariën et al., 2005). 
 
With the exchange of pZAC env sequence in pMJ4 we could improve the infectivity and 
replication rate of the original subtype C proviral clone. The pZAC env gp120 sequence has a 
shorter V1 sequence than that of the described infectious HIV-1 subtype C clones, 
subsequently making the V1 loop more compact. Walter et al., (2009) previously described 
that the shortening of the V1 loop in HIV-1 strains increases viral interactions with CD4, 
leading to more stable binding of the virus with CD4, which enhances viral entry and 
subsequently improves viral infectivity. Glycosylation patterns of the V2 loop facilitate env 
interactions with CD4 and CCR5 and have been shown to affect viral replication kinetics. 
Thus, the higher number of glycosylation sites in the newly described env gp120 sequence, 
compared to that of MJ4, may also play a role in improving viral infectivity as seen in the in 
vitro cell culture assays (Ly & Stamatatos, 2000).  
 
The ZAC sequence also has a larger V4 region, compared to the other infectious African 
subtype C strains. In this respect it is more similar to the Indian C-type strains. Larger V4 
sequences may play an important role in the ability of infectious viruses to bind more 
efficiently to co-receptor molecules and it has been shown that they probably enhance the 
repertoire of co-receptor usage of HIV-1 subtype C (Walter et al., 2009). The replication 
kinetics of the new infectious pZAC clone is much higher for a Subtype C strain of African 
origin than previously described. 
 
The gold standard to study and to develop antiviral drugs against HIV-1 diversity remains in 
vitro cell culture assays. In Europe and America this has ultimately been based on the HIV-1 
subtype B infectious strains. As HIV-1 subtype C predominate in Sub-Saharan Africa we 
aimed to construct an infectious subtype C molecular clone representative of strains in this 
region and which can be used in in vitro cell culture assays comparable to that of HIV-1 
subtype B. The newly characterized infectious HIV-1 subtype C strain, pZAC should be 
useful in those studies.  
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Sequence data 
The ZAC sequence reported here was submitted to GenBank and is available under the 
following accession number: JN188292. 
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Figure 1A: Modification of pMJ4 with the use of marked restriction enzyme sites. 
 
 
Figure 1B:  A neigbour-joining HIV-1 subtype C phylogenetic tree. Infectious clones are 
indicated with a ♦. 
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Figure 1C: Transient viral titer on TZM-Bl 
 
 
Figure  1D: Transient protein expression of HIV clones. 
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Fig. 1. Molecular characterization of pZAC, an infectious proviral clone from Cape 
Town, South Africa. (a) Cloning strategy used during the study. The U3 promoter of 
pMJ4 was replaced with a CMV-IE promoter, as indicated. The new proviral clone, pcMJ4, 
was used as a backbone for further characterization of pZAC. The enzyme restriction sites 
used for cloning are indicated. (b) Phylogenetic analysis of HIV-1 subtype C infectious 
clones. A Neighbour-Joining tree was drawn from the infectious HIV-1 subtype C clones, 
compared to a HIV-1 subtype C reference set (dataset obtained from BioAfrica.net). 
Evolutionary distances were calculated using the Maximum Composite Likelihood method, 
with a bootstrap test of 10000 replicates. The branch scale, indicating the evolutionary 
distance, is indicated. The Indian and African strains form two unique phylogenetic clusters, 
with the newly described ZAC sequence showing similarity to the Botswana HIV-1 subtype 
C sequences. (c) and (d) Transient virus titer on TZM-Bl and Western Blot analyses of 
infectious proviral clones. After transfection of HEK 293T cells, cultured supernatant were 
titrated on HeLa TZM-Bl indicator cells to determine the transient viral titer of HIV proviral 
clones.  HIV-1 Gag was detected with an anti-p24 specific anti-serum. GAPDH was used as 
loading control while GFP served as indicator of transfection efficiency. The pZAC-derived 
clones have a higher viral titer on TZM-Bl cells, as confirmed by Western Blot analysis, 
compared to that of both pMJ4 and pcMJ4. Titers and standard deviation were derived from 
three independent experiments.  
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                     Signal peptide         x        
        
NL4-3       MRVKEKYQHL WRWGWKWGTM LLGILMICSA TEKLWVTVYY GVPVWKEATT TLFCASDAKA 
ZAC         ---MGITRNC QQ-.-I--IL GFWM----NV MGN------- --------KA P--------- 
MJ4         ----GIPRNW QQ-.-I--SL GFW..I---V MGN------- -----R--K- ---------- 
HIV1084i    ---RGIQRNY PQ-.-I--IL GFL..--YNG MGS------- --------K- ---------- 
IN.D24      ---GGILRNC QH-.-I--IL GFWMF---NV VGN------- -----R--K- ------E--- 
Indie_C1    ---RGTLRNY QQ-.-I--VL GFWM----NG GGN------- --------K- --L-------    60 
                    x 
         
NL4-3       YDTEVHNVWA THACVPTDPN PQEVVLVNVT ENFNMWKNDM VEQMHEDIIS LWDQSLKPCV 
ZAC         -ER------- ---------- ---I--E--- -K-------- -K-------- ---E------ 
MJ4         -EA------- ---------- ---IE-K--- ------E--- -D-------- ---------- 
HIV1084i    -ER----I-- ---------- ---L--E--- ---------- -D-------- ---------- 
IN.D24      -EK------- ---------- ---LD----- ---------- -D-----V-- ---------- 
Indie_C1    -ER------- ---------- ---I--G--- ---------- -D-----V-- ----------   120 
 
  xxx   V1         V2  
 
NL4-3       KLTPLCVSLK CTDLKNDTN. ...TNSSSGR MIMEKGEIKN CSFNISTSIR DKVQKEYAFF 
ZAC         -------T-N --NYI-.... .......... ..DTT--T-D ----MT-EL- --RK--H-L- 
MJ4         -------T-N -KNVTSK... ....DINITS NAEM-A-M-- -----T-EL- --KKQ---L- 
HIV1084i    -------T-N ---V-S.... .......... ANSTSEDMR- ----VT-ERK -RKKL-Q-L- 
IN.D24      -------T-E -NHVNITY-A TIHNATDQAS FNKTREQMR- ----VT-EL- --KKS---L- 
Indie_C1    -------T-E -RNVSR.... ...NV--YNT YNGSVE---- ----ATPEV- -RK-RM--L-   180 
 
     xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
 
NL4-3       YKLDIVPID. ........NT S...YRLISC NTSVITQACP KVSFEPIPIH YCAPAGFAIL 
ZAC         --P----LNE N..FNSSA-Y -..E----N- ---A-R---- ----D----- ------Y--- 
MJ4         -------LTN ...DNASE-A -..E----N- D--T---S-- --T-D----- ------YV-- 
HIV1084i    -R-----LK. ...NSSSS-F -..E----N- ---TVS---- --N-D----- ------Y--- 
IN.D24      --I----LKE EKKNNSSE-N -SGH----N- ---A------ --T-D----- --T------- 
Indie_C1    -G-----LN. ..KKNSSE-S -..E----N- ---A------ --T-D----- ------Y---   240 
 
NL4-3       KCNNKTFNGT GPCTNVSTVQ CTHGIRPVVS TQLLLNGSLA EEDVVIRSAN FTDNAKTIIV 
ZAC         ---------- ---N------ -----K---T ---------- --EII---E- I-N-V----- 
MJ4         ---------- ---N------ -----K---- ---------- -KEII---K- I---V----- 
HIV1084i    ---------S ---N------ -----K---- ---------- ---II---E- L-N-V----- 
IN.D24      --KD-K---- ---S------ -----K---- ---------- --EII---Q- L-N------- 
Indie_C1    ---------- ---N------ -----K---- ---------- -GEII---E- L-N-V-----   300 
 
         V3  xxx 
 
NL4-3       QLNTSVEINC TRPNNNTRKS IRIQRGPGRA FVTIG.KIGN MRQAHCNISR AKWNATLKQI 
ZAC         H--E----V- ---G------ V--..---QT -FAT-EI--K I-E------E DQ--K--HRV 
MJ4         H--E----E- ---G----R- V--..---Q- -YAT-DI--D I-A------E S---KI-YRV 
HIV1084i    H-KDY---V- ---------- M--..---Q- -YAT-EI--- I-E------G S---N--QRV 
IN.D24      H--E----I- ---------- ---..---QT -YAT-DI--- I--------G .---E--YNV 
Indie_C1    H--Q----V- ---------- ---..---QT -YAT-DI--D I--------- D---E—_QRV   360 
 
        x     V4  x 
 
NL4-3       ASKLREQFGN NKTIIFKQSS GGDPEIVTHS FNCGGEFFYC NSTQLFNSTW FNSTWSTEGS 
ZAC         SE--E-H-P- .---K-GPPT ---L--T--- ---R------ -TSS---G-Y MRP.....N- 
MJ4         SE--K-H-P- .---Q-D-PI ---L--T--- ---R------ -TSK---G-Y N........- 
HIV1084i    KK--G-H-P- -T--D--P-- ---L--T--- ---R------ -TSK---G-S E......... 
IN.D24      SR--A-H-P- .---N-TSP- ---L--T--- ---------- -TSV-----Y NHT-KQF.S- 
Indie_C1    GK--A-H-H- .---K-AS-- ---L--T--- ---R------ -TSG---G-Y MPTYMPN.-T   420 
 
    xxxxxxxxxxxxxx    CD4 domain           x__x 
 
NL4-3       NNTEGSDTIT LPCRIKQFIN MWQEVGKAMY APPISGQIRC SSNITGLLLT RDGGNNNN.. 
ZAC         TGNTSNS--- -H-K------ ---G--Q--- ----A-N-T- K------I-- ----QT--.. 
MJ4         TGDTSNS--- -S-----I-- ---G--R--- -S--A-N-T- K--------- -----ETS.. 
HIV1084i    ....SNS--- ---K---I-- ---G--R--- ----A-N-T- K--------- -----G-G.. 
IN.D24      PYNDTNS--- IH-K---I-- ------R-I- ----A-N-T- K--------V -----TES.. 
Indie_C1    ESN.SNS--- I------I-- ------R--- ----A-N-T- T--------V H---IKE-DT   480 
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        V5 xx  
 
NL4-3       ..GSEIFRPG GGDMRDNWRS ELYKYKVVKI EPLGVAPTKA KRRVVQREKR 
ZAC         --TN-T---A ---------- --------EV K---L---T- -----E---- 
MJ4         ---I-----A ---------- --------E- K---L----S -----E---- 
HIV1084i    --.T------ ---------- ---------- ----I----- -----E-G-- 
IN.D24      -NNT------ ---------- --------EV K---I---A- -----E---- 
Indie_C1    ENKT------ ---------- --------E- K-------A- -----E---- 530 
 
Fig. 2. Amino Acid alignment of Env gp120 of the HIV-1 subtype C infectious clones. 
The variable regions (V1-V5) are marked as well as the CD4 binding domain. pZAC has a 
shortened V1 loop and a slightly enlarged V4 loop, compared to that of pMJ4 and 
pHIV1084i. 
 
 
Fig. 3. Growth kinetics on PBMCs. Infectious viruses (MOI: 0.05) were cultured for 8 days 
and supernatant were titrated on TZM-Bl HeLa cells to determine the viral titer as indicated. 
Experiments were done in triplicate. NL4-3 had the highest replication capacity, whereas 
MJ4/ZACenv and ZAC replicated better.  
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Chapter five 
 
5.  Discussion 
 
5.1  HIV in South Africa 
There are currently 5.7 million people infected with HIV in South Africa, making it the 
country with the highest number of infections in the world. This accounts for almost 12% of 
the total population (UNAIDS, 2011). The annual antenatal survey estimates that 
approximately 29.3% of women between 15 and 49 are infected. High variations are also 
seen between the provinces of South Africa, with the Western Cape having the lowest 
prevalence (16.1%) and Kwazulu-Natal the highest (38.7%) (South Africam Department of 
Health, 2010). The early South African HIV-1 epidemic was dominated by HIV-1 subtypes B 
and D, associated with the homosexual population (Engelbrecht et al., 1995). This has been 
replaced by the fast spreading subtype C epidemic which is more commonly found in the 
heterosexual population (Jacobs et al., 2009; Van Harmelen et al., 2003). Recently more and 
more non-B, non-C HIV and other recombinant strains have also been identified in the South 
African population (Wilkinson and Engelbrecht, 2009). 
 
By May 2011 there were an estimated 1.4 million people receiving ART in South Africa, 
with the number still increasing. Current therapy guidelines state that therapy be initiated at a 
CD4+ cell count of 350 cells per mm3 or below. Treatment should be given to all infants 
under the age of one, regardless of their CD4 count and all infected pregnant women should 
participate in a PMTCT prevention program. In the Western world it is recommended that a 
resistance profile be done on all HIV-1 infected individuals before the start of ART, as 
approximately 10% of patients have primary drug resistant strains (Arasteh et al., 2005). 
However, because of the high number of people infected in South Africa and the financial 
burden of treating everyone, such genetic test for everyone is currently impossible. During 
this study we investigated the genetic diversity of HIV-1 in Cape Town, South Africa for the 
period 2002 to 2004. We found that 95% of circulating strains belong to HIV-1 subtype C, 
3.6% belong to subtype B with a subtype G and CRF02_AG strain also being identified. 
RAMs were also identified in five sequences (3.6%). These include three (2.1%) NNRTI 
mutations, one NRTI (0.7%) mutation and one PI (0.7%) leading to resistance against to 3TC, 
NVP, EFV, and DLV. Bessong et al., (2006) also identified resistance to NVP (5.7%) and 
3TC (8.5%) in rural settings in South Africa. People starting therapy with pre-existing HIV 
resistant strains often have a higher chance for failing ART (Shafer et al., 2007). With the 
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progression of the national ART program, it is important to monitor the resistance profile of 
naïve and treatment-experienced patients. 
 
5.2  HIV-1 subtype C 
HIV-1 subtype C is currently the most prevalent HIV-1 subtype worldwide and therefore 
there has been much focus on the development of a subtype C candidate vaccine (Van 
Harmelen et al., 2003). HIV-1 subtype C was first discovered in North East Africa, 
particularly Malawi and Ethiopia in the early 1980s (McCormack et al., 2002; Salminen et 
al., 1996). The oldest documented case, confirmed by DNA sequencing comes from a 
Malawian patient infected in 1983 (McCormack et al., 2002). The most common ancestor of 
HIV-1 subtype C dates back to the 1960’s, which is consistent with data that HIV-1 group M 
originated in the 1930’s (Travers et al., 2004). It has since spread throughout the world and 
has become the most dominant subtype in Sub-Saharan Africa (Gordon et al., 2003) as well 
as East and Central Africa (Vidal et al., 2000). There have been reports of subtype C in 
numerous countries, such as Brazil, China, India and Russia (Osmanov et al., 2002). In many 
of these countries subtype C variants with intersubtype recombination have also been 
characterized (Pollakis et al., 2003).   
 
HIV-1 subtype C has very unique genetic characteristics which distinguishes it from other 
HIV-1 subtypes. These include the presence of extra NF-κβ enhancer copies in the LTR, Tat 
and Rev prematurely truncated proteins and a 15 bp insertion at the 5` end of the vpu reading 
frame. Subtype C also has a relatively conserved env gp120 V3 loop, with the virus showing 
preference to using CCR5 as its major co-receptor irrespective of the stage of disease 
progression (Ariën et al., 2005), compared to subtype B which switches to CXCR4 and 
syncytia inducing during late stage of infection. It has been hypothesised that differences seen 
in the LTR promoter may be responsible for this rapid expansion of subtype C. The 
efficiency by which subtype C is transmitted from one person to another has been suggested 
as a contributing factor to subtype C predominance. However, subtype C does not have a 
higher fitness level compared to the other HIV-1 subtypes (Ariën et al., 2005) and it is still 
exactly unclear why HIV-1 subtype C has become so predominant. Improved tourism and 
migration to and from countries with a high HIV-1 subtype C prevalence rate are probably 
also contributing to the spread of subtype C variants worldwide (de Oliveira et al., 2010). 
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5.3  HIV-1 in Tanzania 
The HIV prevalence in adults (15 – 49) in Tanzania is currently 5.7% (UNAIDS, 2011). By 
the end of 2010 approximately 200 000 patients in the country were receiving ART through 
CTCs. HIV-1 subtypes A, C and D, and recombinants thereof are frequently being detected 
(Herbinger et al., 2006; Ndembi et al., 2008), as with our own observations. During this 
study we analysed viral strains from treatment naïve patients from Mwanza, Tanzania. 
HIVDR was determined in 88 sequentially enrolled ART-naïve patients (mean age 35.4 
years). The frequency of HIVDR in the study population was 14.8% (95%; CI 0.072–0.223) 
and independent of NVP-resistance induced by PMTCT programs. Patients > 25 years had a 
significantly higher HIVDR frequency than younger patients (19.1%; 95% CI 0.095–0.28) 
versus 0%, P = 0.0344). This alarmingly high frequency of HIVDR could have been 
generated either by direct transmission of drug resistant viruses from sexual partners or 
through the natural pool of quasispecies in each individual patient following undisclosed 
ART. Both factors probably contributed to the observed high frequency of RAM in our 
Tanzanian study group. 
5.4  HIV-1 diversity, ART and HIV-1 resistance 
An ideal HIV vaccine should be active against all currently circulating strains. However, this 
is highly unlikely as HIV has an extremely high genetic diversity and easily mutates to 
escape the immune system (Nickle et al., 2007). ART has achieved success by keeping the 
viral titer under control. The life expectancy of individuals on ART has dramatically 
increased over the last few years, with therapy regimes continually improving. However, as a 
result of selective pressure from therapeutic drugs, HIV develops mutations which causes 
resistance to ART drugs (Johnson et al., 2003; Thompson et al., 2010). Most of what we 
know about HIV-1 resistance is based on observations with HIV-1 subtype B, as this is the 
most common subtype found in Europe and North America (Hemelaar et al., 2011). Only 
recently has Nauwelaers et al., (2011) developed a synthetic HIV-1 subtype C phenotypic 
assay, comparable to that of subtype B. It has been shown that genotypic resistance profiles 
may differ between HIV-1 subtype B and non-B subtypes. An example is the K65R RT 
protein change, which accumulates more easily in treatment failure patients of HIV-1 subtype 
C. HIV-1 subtype C isolates have a higher IC50 baseline value for the PI ATV, compared to 
the NL4-3 HIV-1 subtype B laboratory strain. Other RAMs not typical of subtype B include 
the RT change V106M and the PI changes I93L and M89I/V (Martinez-Cajas et al., 2008). It 
has also been found that some HIV-1 strains have lower pathogenic fitness levels than other 
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strains (Abraha et al., 2009). Therefore, it is still unclear to what extent HIV-1 genetic 
diversity will play a role in the ultimate successful treatment of HIV/AIDS patients. We 
should keep monitoring the HIV-1 genetic strains worldwide, as well as be aware of the 
RAMs which HIV strains may develop while patients are on treatment. During this study the 
HIV prevalence in the treatment naïve populations from Cape Town, South Africa and 
Mwanza, Tanzania were carefully investigated.  
 
5.5  Vif function and diversity 
Little is known about the influence of Vif diversity in HIV-1 pathogenesis. Vif is an accesory 
HIV-1 protein that blocks the antiretroviral activty of the APOBEC3F/G protein family 
(Conticello et al., 2003). Thus by helping degrade APOBEC3F/G, HIV infectivty in the 
producer cell is significantly enhanced. Vif also prohibits APOBEC3F/G being packaged into 
viral particles, although the exact mechanism is still unknown (Argyris and Pomerantz, 
2004). Viruses lacking Vif are susceptible to being hypermutated, leading to non-infectious 
virions being produced (Simon et al., 2005). Some reports also suggest that long-term 
nonprogressors have a higher number of mutated or defective Vif proteins (Hassaïne et al., 
2000; Yamada and Iwamoto, 2000). Therefore, during this study we also investigated HIV-1 
vif sequence diversity in Cape Town, South Africa. As Vif-host interactions might be 
considered for future vaccine strategies, it is important to investigate the diversity of these 
genes (Miller et al., 2007). 
 
5.6  Development of infectious HIV proviral molecular clones 
Much of what we have learned about HIV biology has been with the use of studying 
infectious HIV proviral molecular clones in in vitro assays. Initially infectious clones were 
generated through lambda phage cloning, however this was a laborious and time consuming 
process (Adachi et al., 1986; Gao et al., 1998). New infectious molecular clones are known 
being created through long range Polymerase Chain Reaction (PCR) methods, as the fidelity 
of polymerase enzymes has been improved dramatically over the last few years (Cheng et al., 
1995; Hogrefe and Borns, 2011; Michael and Kim, 1999). With PCR cloning techniques 
however, HIV genome errors often have to be fixed first before the proviral molecular clone 
is infectious, as a large number of primary HIV isolates circulating are often non-infectious 
(Ariën et al., 2005). Chimeric hybrid clones or simian human immunodeficiency viruses 
(SHIVs) have also been widely used to study HIV and SIV, especially in animal studies 
(Song et al., 2006; Smith et al., 2010). 
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During the course of this study we used a cultured South African HIV-1 subtype C strain to 
improve the replication capacity of a previously described proviral molecular clone MJ4 
(Ndung'u et al., 2001). We added a CMV-driven promoter to pMJ4 to improve expression 
levels of virion proteins, which led to an approximate fourfold transient increase / production 
of infectious virus. The newly developed pcMJ4 clone was subsequently used to characterise 
the patient derived sequence of ZAC and to develop the more pathogenic pZAC infectious 
molecular clone from Cape Town, South Africa. The new infectious clone should be used in 
in vitro assays concerning HIV-1 subtype C. 
 
5.7  Future perspectives 
The high level diversity of HIV-1 has made it very difficult to obtain a vaccine against an 
epidemic that has plagued us for the last twenty years, although antiretroviral therapy 
continues to improve. The gold standard to study HIV-1diversity remains in vitro cell culture 
assays. In Europe and America this has ultimately been based on the HIV-1 subtype B 
infectious strains. As HIV-1 subtype C predominates in Sub-Saharan Africa we aimed to 
construct an infectious subtype C proviral molecular clone representative of strains in this 
region and which can be used in in vitro cell culture assays comparable to that of HIV-1 
subtype B. The newly characterized infectious HIV-1 subtype C strain, pZAC can be used in 
pathogenesis studies and help to characterise currently circulating as well as drug resistance 
mutations of HIV-1 subtype C.  
Although the HIVDR in the treatment naïve population in Cape Town, South Africa, at the 
time of this study was below 5%, in rural South Africa the levels were reported as high as 
8.5%. In Tanzania we found that the HIVDR in the total population was 14.8%, much higher 
than has been previously reported. Therefore we recommend that all HIV-1 patients should 
undergo a HIV-1 genotyping test before the start of ART, although this is not always possible 
in resource-limited settings. 
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Appendix A: Gemeinsam gegen HIV by Robert Emmerich. Published online on the 
University of Würzburg news page (www.idw-online.de/pages/de/news267754). 
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Appendix B: Optimismus auch in schwierigen Situationen.  
 
Studierende aus Südafrika in Deutschland by Sabine Hellman, Lemmens Medien GmbH, 
Bonn (http://laenderprofile.gate-germany.de/de/). 
 
